{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.13.0",
    "document_metadata": {
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "licenses": "CC BY 4.0",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "name": "choi2014",
      "version": "1.0.0",
      "authors": "Rana Aldisi",
      "description": "This file encodes the article Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia by Choi et al, 2014"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/7e4be528f12abd28be768b62402fba6e083eaf9e/export/hbp-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "MIRBASE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "CTO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "SCOMP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns",
      "SFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "TAXONOMY": "^\\d+$"
    },
    "namespaces_uncached": [],
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_list": {},
    "path": "/Users/cthoyt/dev/knowledge/hbp_knowledge/choi2014.bel"
  },
  "nodes": [
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "3',5'-cyclic AMP",
      "id": "e634e1d295920557f5cf0c1b3fd2bf18d082b00fb983d6632b989552d1ba51e14a88952b3abfc55d7ab65f035c7e90d951497cfa11719f0492edab0ddb91813a"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "EC 3.1.1.7 (acetylcholinesterase) inhibitor",
      "id": "f5115583612f3f2c40ebc54f2c528dbe7732517483538bd78de15d36df42904885a4fb82e5b4feac53e21bbdcf5c7e8e78c1985c4ff40c3fe99509119cf8984b"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "amyloid-beta",
      "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "antipsychotic agent",
      "id": "8732984253db073107c8e4c4479f465928e8bce05a3a153e74bda0829bbe0bd97f02336d237ba18094ce08701b338993072aeb578ea971a44fa99449c149c0a3"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "acetylcholine",
      "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "amphetamine",
      "id": "972be28229609615d2e61230ce6c1227f009d2df53db596e1f210bf805f1b89eb096eab76c3c51eedaa306a2cd9c6588eee5fff51110e401709063a55c895db6"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "apomorphine",
      "id": "5ccc0afce4607e7f1133dfe1e62fca66debfe9d7e10fea1604e3ff8ac8401974232a0417220aa843c0c671a33f7c4afd48dbd0314d79b6244b9be526b808332a"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "donepezil",
      "id": "e1d832febdffe3cc8c4fa21718e0b21719272a1a10c2945cdd3b36cc6ff66c3ec70289ed1ddc3a7a6b79ca44a4bc0fac6ecb12683fc043cdac26b952f7cf5223"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "galanthamine",
      "id": "829d639ffa1b9cf0dc884553079510b093dde8971a129c58afff24ea1d1103f0db214945577b66dc941db450715ecdfe7951a8498afafb02cb1653b60845fc57"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "rivastigmine",
      "id": "317d5b18448e148088204c7a7dce78316c0ea8b56c70a7adaffe344826b17688e05873b2746050d29c18ae658658e81a2d775ba56b6f5abf8821f4eaca725064"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "scopolamine",
      "id": "3a1bb34f4041183c02d322a9719f3efbadef9bf26804f46b729cd13c9107e3b2fe500006cdd50e18fd01abeca0a45aca2a8475a44a9f978315c17023fe186bd0"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "tacrine",
      "id": "c1560ac01f8b46a59d909fe73d5cd84dad7f9c83d170b6000eac634fc33a12091ff9cd73964d98a326de73abd7f9dd033ae78f40624c6984e29ad84d21436720"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "xanomeline",
      "id": "2fc0c8095fa7470cf35b39ec64fdafb13d4aacaa5cf5fccb346bad55c7db083afc2172727fe8e5e1b11eedbf583482aa264cc408edc9e39f1d6e3a6ce1771a02"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "amyloid-beta aggregates",
      "id": "1d739f6eba3532950fc068e81f7aea675ce76d42a049b5a301ad8bccf2f503d6c2a79c9d417d4d35cc760c340b5db2513536b3c420156a92bda3605be3537740"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "sAPP-alpha",
      "id": "7e0d346932e47222255dbd0e3b132a0dbeb5ba12373ac498350cabcb9d55c68f9de35471d8a7b9d9ac04e97b62b9699eef7226e0a7827d4b6be0d24acb31e70e"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "VU0152099",
      "id": "94854729534edb70c53f626f8f1180b22a623dfc158e07ea72ca21e2f00f171854f272f142e482d50b362e6ca5f3d2ff1c48ad01bf19a82e4ce9dac19f058f5f"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "VU0456940",
      "id": "081c61d5ca506ec9e02cd6efe043f96663f8348d430c9f5e462fd97cce74cc3f399a5e277920874759593bdde6ab2b72ae912927c57b711146c8c28a8c3998f3"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "VU10010",
      "id": "7e336f592834fda79443c9eaae4f27822e0e9f4b3835266a641b035a319501c9ba46f23988603074d5410b1eb9f102ed56eecac6a2ca2b56f90149cda754be6e"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "1-(1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl)-1H-benzo(d)imidazol-2-(3H)-one",
      "id": "bb6bc6941a6b064cd867bc71f1b6f00fd6c710c549fc4289df8cad43c0336195f72fd5d0c96cc64e5f5fc70ece0a4863889b1365d785e94084e43dece76550a0"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "1-(3-(4-butyl-1-piperidinyl)propyl)-3,4-dihydro-2(1H)-quinolinone",
      "id": "656617b3484cb4692bc99b750f41639fcafbbfe4286420d50f2199d7912e305aa1ba9a90dbe24b9ea966cce9cf5a3a1b907cd7c9fc2b76ed857ecf26c86a2367"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid",
      "id": "7a8a9305fe3a5d5318b66eec8d6927f2c93c966c1c09af5650d426d5a65aaf808a41ff08e92f2905339a5db41490a09950fd7e07e44d007f7ef1569db8bcca28"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "3-amino-5-chloro-6-methoxy-4-methyl-thieno(2,3-b)pyridine-2-carboxylic acid cyclopropylamide",
      "id": "8ffaaa923717711fb226c835f69baf74b4f9defdae80c17828cfa0160b5fae0c8b3f877db5b948fccd71af59cab59ebb78f108dff0eaec015701780f58ff0af9"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "3-amino-N-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide",
      "id": "0285c6779c37d10cc127b849a987a932274e798deadd7b298f853c5ade39fe52216308b2a925c656d1f2e3b3c40251ea6d58deb493e7f8c640b1b19c53d6c2ed"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "4-(3-(4-butylpiperidin-1-yl)propyl)-7-fluoro-4H-benzo(1,4)oxazin-3-one",
      "id": "e28566a2642096802d1fbbb58c63728d8c64f72835e5b40eb74e0ae2cc0de69f0e4c859ba934ed9c538faac7c380fe3cbf9747afbd5b852b8895f40d74422f72"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "6-(4-butylthio-1,2,5-thiadiazol-3-yl)-1-azabicyclo(3.2.1)octane",
      "id": "6646984372801eaab4c4b6b3f93fd9fc0abd741c4587ed3351b91a61eaabf2545072acf175a585e013ea2f2d7ecfa7d52182ec0cc857b031cea683b0eb6bef95"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Cardiovascular System",
      "id": "dc476bcb3aab217e25127fe06449ca8eef77c13ddb8771a6e1cc0c68c04a447f7b3e1caf7f5698785e5c61d08852d928fbbd2c6373f72f9f5528fb10f92944ae"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Cerebral Cortex",
      "id": "d570f84dde08e8887b0ba3cb15f79f0f4378d9c7417d64d2a363380e917313da6df600a00c005cef2a697249feaeb07da95f500476083923a8f77b9caedb6e35"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Cholinergic Neurons",
      "id": "475e93ca136a9e7794a0aa5f656e5e5514ae3be3984ee430b1c69e597fa87e955ab73e3aa428c790e154477727ce382f73ecadc9ea6ee58ce4366c0b4ed73765"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Corpus Striatum",
      "id": "a247be869b9cb7ebed239b8bf5a38164896959a93569c5d8c3c7f34b351ee822a0f8176f09b51343dc7d84df7cfd3236071444ac447832e10bb565f55c791b5e"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "GSK 1034702",
      "id": "917009eb7bdc4ad5517a2bbf06828ea51ff491d390a03b5d74a35ffc6f43c5a5cd7c4567ba60484b859aeebe2e4df40d3c72edb376384476671fb4c33a46fe0b"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Gastrointestinal Tract",
      "id": "30ff2f20b1a4cdbe594a0acaf78deba2a52d30d9b8ac78c484832500abf9269671ba6998d96c7085398ed2955c3a0df2a49a44aa728f6c0bd6c171e3b09320ce"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Inositol 1,4,5-Trisphosphate",
      "id": "c9cc95a6599f6a829adfb23ae4f56b2f8b80f26fb5b972a55ef53feeca2a7dbe8b3312b7c82705cd2a0d1fd76f6a542c3f9c97906220eaffac927e7e1e6338d8"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Muscarinic Antagonists",
      "id": "75a97f283dd894fdc3ded0ed0a09056bf38f6eb51902e447e2fabaf62e60cad27ca8f60ddc28e2d5b102d3e92184d432470479544223cd006440fe3e0210103f"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Prefrontal Cortex",
      "id": "a46eedf8b35d8b1ceb910ec59f492474dbda49456c714b84901d2f45a89624e05a4cf1cb783df91f56f184d848d9155e8f910bd96a89aababd480d4d61b72007"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "VU 0405652",
      "id": "6bf1d2ceeec73ad37bb3b5f41af731fe9d92bc62a89efb2f9f5a6c2c6a138eedffd6eaaeba66e17badc479e7d771000e81d6004abf700f18a9e333f67a9ad14c"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Hippocampus",
      "id": "caff813aaa3f73ff030fa368884d30438c42f1f22aa2b372a08646bda846d5a6ee94d85bb4de2153aaa55ba41bd82a361353793ade6e39bccfe43c75f5a95750"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Neocortex",
      "id": "61181eb06c0d951f88e6481ee83dbd78fcc1daa349f16b98195ea0e074f543dd06be3d8f2f244362af223c7b475e6c125a03ae27d63edc655e6fd85001a9a8ee"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Neurons",
      "id": "130131072f276d163b9e361a4ca4814f1d254907d297db502ccb4f6e75dff10db1f2b384bb435c9b46e91310d585aea1db3108e00905a31bb1388ccda1f0c643"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "VU0357017",
      "id": "e484967f34ab300b97c9cd47a24b04c97464179c0b5d7fc096705723f9dbf6fd1f4b069b378e71477b02ad347a4af9429d044c5cfe8629b1157eb105180d09a3"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "behavioral fear response",
      "id": "7812ec5ba62003b503db9e2050962636dcccc144af2b1cdf641e6db9202b38e8f220920f159f25f8bae030515ff74f78d3aaf09500080f736a362613a0ec3174"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "calcium ion transport",
      "id": "7c1debe8c5aa50112a2768a7f845bfa93e1a6d2b911259a74f85603b0bd6b85e9b5f7092e547476c7cd51d82f313134048069f3cc2600eabc1ec0b33e88642b8"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "cell death",
      "id": "b2ecb9d87645a0a7d5efbe2c9eeeaa14a705a36b6cdf787e071ba334fdd12b4caaf12b88508b99a8974005549b3c8123c9481c5d969630df072082b07e4dc586"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "dopamine secretion, neurotransmission",
      "id": "52a41364e5d8b0d9e1cd9d7d77d5afeb6f60e5a594fe5fc80681ad0988708fbb83197c7049f4b9ca9357ed8eeb84b045b66abbead4a7707cd1f5fbe5ec95c2a0"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "excitatory postsynaptic potential",
      "id": "7530abec480fef9088630c7c75659c3319b25c0203b3f1e783da5dad1de92f5a07a2124c9fb223f91468243fc3f14894ac43b624ced9fa8405b9151b240b85e1"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "gamma-aminobutyric acid signaling pathway",
      "id": "30980a1ca94ae7c6e7bdbb688afa4d5532f477f22981eaaf4e452a06b36b33ff260ac6d63a8d214e2cb0c92514edb5cb2b282c38e13418eca1e9ace557bdfb63"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "long-term synaptic potentiation",
      "id": "90aca567c87981f32f4001b6386423cf473ef52decf04004bd136ab80fd9088c2698b76c8baf740f8e282b107790d3c88130dc99225bab73b22516859dc4203a"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "prepulse inhibition",
      "id": "f7ed85914a501d74f04fed1618dd9a955f0067bb9e13ea771b0bde3aedc6549f2880b775db920669f6a4b5611daa23fca223e2b72f53bba86df69430b1270649"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "synaptic transmission, cholinergic",
      "id": "4238cec14ccdcd7b90d308eb0687f5775f5b1ed79362c1d84004721894a52040968a92b357a6bf971a144e903a9b441d8be9ba5ee78e5e039c5f83c167933575"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "synaptic transmission, dopaminergic",
      "id": "30e4d389cce3682af2cd604d08a33dd5d8aa502d5fda93a9cf7ad8ee4d033ee8e9e72d4fb7082b622fae5d7648457514171c04400da110e5eeee4f6d38b23fd8"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "synaptic transmission, glutamatergic",
      "id": "68a9f5219c953044883133bf5f935c2f9a074b8e719aa33dc0766bba8dd98b92cefd134205b93bd6f586b594e1438d307a554c9771bccd03dc6acf03e09bb82c"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "behavior",
      "id": "9a101ba3d87b5d6d86780d7ab27c7ab65e2d60e8abbe894683aa3ad6755eb311c595c8a088174655a14224a317985b6ec4db3d3c829671b156af6e3f4d6cae36"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "cognition",
      "id": "8d73f2caa1c473289d5f37cbdd4ad391a120cdbdf2356b373070c2a7b2bc0c785eaa620782fa2dd947c666100f0a169e81f35864f359cadf3e1550962fcc4127"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "learning",
      "id": "24fec79fe31de63921d3028dd6ce5e335372d8d221877724830f05136d6c879daa7585768231b87272f0ebb8a7f6038f1aabb8785a626cca0c95b33018cc1633"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "locomotion",
      "id": "e39e344818f1c8be3c26236deebbb894a1271eb3c094358751fb6cb220c0e74e1b41c6bb643891cb9835caff7f7a07e32061891beccec54ccee5cfb83b59e23e"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "memory",
      "id": "87795d00588bdf77d28229ad379d58f00922f6339902a803d0672cc15e669269f8fe50785b2851e1e82046f4e1e49920534ec68c0b6911bea5a1b838dbc999cd"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "HBP",
      "name": "neuroinflammation",
      "id": "852fb6af6af67ae4c41cb9012bf15e6b8c45b8c674a761dada1f9f651645f80ec40f0020d722d97ec3f35c51666a87f94d25a7414e9294adac055c9f18d3d2b6"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Neuronal Plasticity",
      "id": "2faf5537d897c15a7721d74776d992d5a44ac80a8ff72cf1807a20f5d844c7812f98e952f4a085b30bac7a44a23fd44f51478048b615422b5fc54b6c05d74cb3"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Aging",
      "id": "175e5d777b693461a2f6189ec21aa1f8324f054bc8acc641df82819a4c04776202053094a1c12915bdfd2244a6a5f639b7008b7f8e9a5ffea3c3b8aaa255d1b9"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "MESH",
          "name": "GSK 1034702",
          "id": "917009eb7bdc4ad5517a2bbf06828ea51ff491d390a03b5d74a35ffc6f43c5a5cd7c4567ba60484b859aeebe2e4df40d3c72edb376384476671fb4c33a46fe0b"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRM1",
          "id": "962b8a84d274a6e78416261efc2137bcf03c8035a7be3138736624f9c08fe9ae92738ac20d9edd54a6ace6ff161f28793df367f2e084e2837fd799e530fddbbd"
        }
      ],
      "id": "5ccc28c5a07ab0d2717e2e189cda869959803bfc806f16873716130879001805c9c920ee3f5c7b935ef5acb7a495b99fddba625655fac503e6e8b5e5db9c3593"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "MESH",
          "name": "VU0357017",
          "id": "e484967f34ab300b97c9cd47a24b04c97464179c0b5d7fc096705723f9dbf6fd1f4b069b378e71477b02ad347a4af9429d044c5cfe8629b1157eb105180d09a3"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRM1",
          "id": "962b8a84d274a6e78416261efc2137bcf03c8035a7be3138736624f9c08fe9ae92738ac20d9edd54a6ace6ff161f28793df367f2e084e2837fd799e530fddbbd"
        }
      ],
      "id": "ddd154651761bd964ffd6a051699147e94699b19f74ff4574729cf8d3946eee6d7b57b6226bc82dd55c8981675613f0429cbbf29477228b1dd69d842171cbec7"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRM1",
          "id": "962b8a84d274a6e78416261efc2137bcf03c8035a7be3138736624f9c08fe9ae92738ac20d9edd54a6ace6ff161f28793df367f2e084e2837fd799e530fddbbd"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "GNAQ",
          "id": "b7fb28864f3be796cef96e3a77a1d483207b6a92b42926882862b04499675e6ef3a8140ba46c7327432474b6ea391e216d36dbce4fba566786a0e07119b727b4"
        }
      ],
      "id": "7a3c36523bccfeaa010cceac6927f2206503a96f8bfcc6ae66de07477adf286784ede866e86120a1729170857bffb8fdbcc5b4084b8cc133831fcb26cbd43782"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRM2",
          "id": "3f3bd4efac7c25609453f906264cb2c3b1de4eb8eee23d557332d4dec2c604a062717a3aaa3a273ae625f7290f3815251c76cd5b9300f8f684085d5526c1cbb5"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "GNAI1",
          "id": "1514ea33e47015bebf4a589921ae3d57bc8d1a2b5754ac9b32fb524e390edf382876062cddbac380420ebbe05231aef1fb72a71c6d7821c8632a91a284de88a7"
        }
      ],
      "id": "ee91e813a886a03ed821dc8d41a6125dee0b2d910863222956e6e3cbf62587e95123298afea2a27f6295c16e17618a867fe3a221ee7d5875ae52facd73e7a5b3"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRM3",
          "id": "321acd12eb1b51bc2a14b21c01d30c83c6a4ce5c3255ef3cf2690b65596f9594c541dc6fe9a23210d952a2fdac2f2d05aa91e4299d1942926ea0932119e338ff"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "GNAQ",
          "id": "b7fb28864f3be796cef96e3a77a1d483207b6a92b42926882862b04499675e6ef3a8140ba46c7327432474b6ea391e216d36dbce4fba566786a0e07119b727b4"
        }
      ],
      "id": "8c984e91da0d1b6192e6c024d8f2a7beac34dcb03c284568044737e7f32f77bd31fb29aa9b054f62ab3d47a86c516788e4719843a9354741ab16f5ff29553120"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRM4",
          "id": "92e568f0e1bc4f13da9c8c905c0894d766ba624982320637733a3097dc72ffc572e6c948301c16f49c9bcbd674b9c3586f48c8643e70247024048401ae1dd969"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "GNAI1",
          "id": "1514ea33e47015bebf4a589921ae3d57bc8d1a2b5754ac9b32fb524e390edf382876062cddbac380420ebbe05231aef1fb72a71c6d7821c8632a91a284de88a7"
        }
      ],
      "id": "e76b96db992453c50cb98422d832108ba9997ab9cd1c6e0ba6cfc5d6ef12ec61e96249a084506beddb01650b562c542ebdc4fd205defd644849c18624f91c3ed"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRM5",
          "id": "7127c478eb6b98b42d944576f420df9017725b724e77febd046f52a2dcc8662133f1e33f6981df086ad9fb9aafb0854d39dffa37131f122cd1e0fd6d4cbc981b"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "GNAQ",
          "id": "b7fb28864f3be796cef96e3a77a1d483207b6a92b42926882862b04499675e6ef3a8140ba46c7327432474b6ea391e216d36dbce4fba566786a0e07119b727b4"
        }
      ],
      "id": "6a3f5d9a714f7a1317b7125d155d3989af998cc2d6c82c671c026d0c13869807f22dc039b21ea19b6031a6ef66e07b6152e4866a44f4a08f2ad0683d48e15e12"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRM1",
      "id": "962b8a84d274a6e78416261efc2137bcf03c8035a7be3138736624f9c08fe9ae92738ac20d9edd54a6ace6ff161f28793df367f2e084e2837fd799e530fddbbd"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRM2",
      "id": "3f3bd4efac7c25609453f906264cb2c3b1de4eb8eee23d557332d4dec2c604a062717a3aaa3a273ae625f7290f3815251c76cd5b9300f8f684085d5526c1cbb5"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRM3",
      "id": "321acd12eb1b51bc2a14b21c01d30c83c6a4ce5c3255ef3cf2690b65596f9594c541dc6fe9a23210d952a2fdac2f2d05aa91e4299d1942926ea0932119e338ff"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRM4",
      "id": "92e568f0e1bc4f13da9c8c905c0894d766ba624982320637733a3097dc72ffc572e6c948301c16f49c9bcbd674b9c3586f48c8643e70247024048401ae1dd969"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRM5",
      "id": "7127c478eb6b98b42d944576f420df9017725b724e77febd046f52a2dcc8662133f1e33f6981df086ad9fb9aafb0854d39dffa37131f122cd1e0fd6d4cbc981b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "DRD2",
      "id": "eb8b732008e044233425ce6aec018b31b93de6fa778d89966f6a6fe3772db2dcc9b963684f1b276901c08810a1bac4ded125b59fe5148306ebdf42f2e390376f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "GNAI1",
      "id": "1514ea33e47015bebf4a589921ae3d57bc8d1a2b5754ac9b32fb524e390edf382876062cddbac380420ebbe05231aef1fb72a71c6d7821c8632a91a284de88a7"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "GNAQ",
      "id": "b7fb28864f3be796cef96e3a77a1d483207b6a92b42926882862b04499675e6ef3a8140ba46c7327432474b6ea391e216d36dbce4fba566786a0e07119b727b4"
    },
    {
      "function": "Protein",
      "namespace": "HGNCGENEFAMILY",
      "name": "Cholinergic receptors muscarinic",
      "id": "bc4355d51c8dab82808ce004ae55c19edf51d387a57828854966a6340f3b344bfdc99f1e6c56624b645fd7994f14bb952a8d8607088690e787c1d934048706cc"
    },
    {
      "function": "Protein",
      "namespace": "HGNCGENEFAMILY",
      "name": "Cholinergic receptors nicotinic subunits",
      "id": "d55bebfe65f49c8e66d1ed0b491af0f01aba4b030a649599e59150e53ed4d3e4cd2199be8863b95c7033ab2185d8d7ea9203e5418faea9d7dcc86757b9bcf4dd"
    },
    {
      "function": "Protein",
      "namespace": "HGNCGENEFAMILY",
      "name": "Glutamate ionotropic receptor NMDA type subunits",
      "id": "04fcb6dc2a3a7372aafa9bcd0a67ae080105125c80681cd13f078d8204e354557b8a3cb1bfac030ca24c27787cd42c4ee35ef15010057fba33439f6190647fd7"
    },
    {
      "function": "Protein",
      "namespace": "MESH",
      "name": "Receptors, G-Protein-Coupled",
      "id": "8142dd42a69802e854b735c63609fe1eeec4476c6c450385d8521ee88737d7ccace5779a4fd5f928e6fad3da843a5dfaa154b013cad14ad23a3af0a28b388234"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Chrm1",
      "id": "45b464adf68bffe5d23f53634e7064e00306d71fed21b4cb0954c6336acf4bc5dae8b45abaf6ee19656e8ca4815e390c82062a5f79cd7dae6da61103e87f5e29"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Alzheimer Disease",
      "id": "00f72839b5d655cb4cb088b0eb8874bd406284d98a2afd0bdd73de0a34adb78af374b0eb26990387f41d3b41cda0e32c1b5ff5f86ed63d0fdc841bac17865541"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Avoidance Learning",
      "id": "47ddf503652d565e868732eb20a49109f3f2620c32de9b741fbf6ed3fc72c5ed5a2a28efc52f67ebbe066725820ac20c1d19deb448cfd1b90b2bb0c4a815159a"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Cognitive Dysfunction",
      "id": "bd78fa3131dd9ef6067a5fe3ee8689c946c79d0da1bedb054d1f4400b9ad0d3ae041837faa0fbacee0af5a57a4cd343d11e73fd53fd05269e3558803a56df69c"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Executive Function",
      "id": "49eccc7c6474d853d3f7d9f266a96b278d78b96c15d0f1691b4c116f7c58d193008d088b30c310c4af65bda65369134dc12957dfb47cb73fc2eecaeeead3efe2"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Memory, Short-Term",
      "id": "6de5faf207aae2571d8732b0e2c8db624aecc9f54517428ed6acad84cafca2ffdb3472c872aee1855f09dfa8c9c69e14fd6f8d8f9a420f992045012133d84297"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Mental Processes",
      "id": "09fb43a38fc6c6fa3d82d1494d6b036956e378f1b2153edf322c743e186f6dbf03d33e41bc2eef97affe3246c4d4f8790cc8943f1d69c0c20ff7fa2d894d65ca"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Neurodegenerative Diseases",
      "id": "95863a6d11beb3bd993523e1c8c7e210d281b0c092553f6a4cf27dd3ecf2fa51b49c5056b8aed6f7ac7c82f99101c34bc9fc0afc3dce117fe011d159ba9e4c89"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Neurofibrillary Tangles",
      "id": "c475029455d40226db06d868a00a3a41d06cefa8e543a1d8f39d53e4799c7ffe095363d7c845684b8e8caaabc2215365a2b4e2f78261e428bc64159b2edf5825"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Plaque, Amyloid",
      "id": "888c33ecabc995942e605aace0106831b95c6e6d4eb99ee4ac4c1de25ff7c58c0cb67b5e941c2d3f3a399aada51a34de03850a43011389d2ab7dae07536cea30"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Psychotic Disorders",
      "id": "70e20ca93acc2bc96dda4f1d7f9d91f213e4188846a55f6ba562f6d3c489ee095289bd631135cbb96349aad7f3154820384e0188a9bfacfd4c50994fb3d0c308"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Social Isolation",
      "id": "b74e45519ac0b09b6289638b167cf8e99402e0bd39bdc8129c54872381bca53250f4b0da6fa41b25983db080c14ba21d18806cc8ea303fd6da256a15207fcd03"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Anhedonia",
      "id": "842038f4478124a4a33908148eb47521d60a699722817c0b45365c85dbcb318bee8d21d7fb89786cf850629c306dacdb4d31d0fc4ae65f15e9cb8b5f90d939b7"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Anxiety",
      "id": "28f6f3390e4ae722f1c1298abe2059a3e03a8a2de93e506a747733d9e980ed28bb2feb1074ec430fda167d3f38e3c1d930e10c16e5e04f371938ce866caba0dc"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Attention",
      "id": "67735e2aaf2e17459a41794138aa7720fd27fb15a51cb7f34b74132b92accef7585efb2a338de3ca85bd2a5ae6bc4f7aac672d1a06b2e19c5e45400ba7b94036"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Delusions",
      "id": "cd322d6f7c86cae1a3997c0bd58a460b404f6f50d1bd936e05dfaa2b58dc3701b70c23b50f9244edb3c42baf1c0239dec16d8f57c9daff7eb3b934e5ef592c34"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Dementia",
      "id": "64388ba3ecebbe4d33fb76bedff9f458276b3ae72f47d401c6852d7f9d7c2abf4b2c4cfb899133f8c6ef9f7eff00a84697a1719fa10fed2e67ec00e97d00ed65"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Depression",
      "id": "1db8d744eac9b5ac408852b1889bb0b09e0054ea091932f1aa44aeeab0ea1b3825912c55c72fb2d25d5848e77d62b1c6a1df2063a2f25ae03e5ca30085922799"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Hallucinations",
      "id": "ad73f79878286e99e48ad8b2ff196bd160666327c138014eae6150c76c71e650c37b2e6e083ba61dfda68dd41a788462fb101c654e6ad160cb434a2076b5df14"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Schizophrenia",
      "id": "574fcb4e3970e1cefa6d4d88a96a5c535f41ece9b53fe0a456e4f7aeb388900e1d66e72e024e1f50c0892640dc2faae2adb82b00a4c66c9aeec93db08dc4a136"
    }
  ],
  "links": [
    {
      "line": 85,
      "relation": "association",
      "evidence": "Schizophrenia (SZ) and Alzheimer’s disease (AD) are two devastating disorders of the central nervous system (CNS) that present clinically with cognitive impairments and psychotic symptoms",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true
        }
      },
      "source": 78,
      "target": 87,
      "key": "0ca2fae5f0104e58d65f5f6beadce16a913e251b3e9b3ebf5c2227a2b969d8e822db1c74f91da817e55184994745c9bb3f6c8b3a81316656fde21ed9520643b5"
    },
    {
      "line": 111,
      "relation": "association",
      "evidence": "Conversely, the most commonly associated symptoms of AD are cognitive in nature and include deficits in learning and memory. However, 50%–80% of AD patients display psychotic and behavioral disturbances that are correlated with poor social and functional outcomes",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 78,
      "target": 87,
      "key": "e70a537388ceb7cf95ecc01c41ca219db3b3db3b0a00ff919caca11b33fb2964dea6aaaa5b758e2fcd798e0d030d0e60942bd81c4c41b5c22650a0ea04ee39a6"
    },
    {
      "line": 177,
      "relation": "association",
      "evidence": "AD is the most commonly diagnosed form of dementia and currently affects approximately 35 million individuals worldwide.7 AD is a progressive neurodegenerative disease that is characterized by a host of cognitive deficits, including impairments in learning and memory. In addition to the well-documented cognitive impairments, AD patients also display behavioral disturbances, including anxiety, depression, and psychosis",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 78,
      "target": 87,
      "key": "1028c21782f67bfa45887cfab7e993f4fad24422ef2090342d9bcbfa17bff5283e554964b4d8292e8c391a3a77d35314cf0bad8a2f78931627e117751ace5f79"
    },
    {
      "line": 86,
      "relation": "association",
      "evidence": "Schizophrenia (SZ) and Alzheimer’s disease (AD) are two devastating disorders of the central nervous system (CNS) that present clinically with cognitive impairments and psychotic symptoms",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true
        }
      },
      "source": 78,
      "target": 80,
      "key": "8524a69ae60db9790675bfb26f3453ebc97ec8fb2dcea024bffab27dde5f0bb0a5e34bdc9fa627c05109afd9156468f9efecbd7499be29ca88154ee550863d81"
    },
    {
      "line": 172,
      "relation": "association",
      "evidence": "AD is the most commonly diagnosed form of dementia and currently affects approximately 35 million individuals worldwide.7 AD is a progressive neurodegenerative disease that is characterized by a host of cognitive deficits, including impairments in learning and memory. In addition to the well-documented cognitive impairments, AD patients also display behavioral disturbances, including anxiety, depression, and psychosis",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 78,
      "target": 80,
      "key": "2a246cf2d9f5fce030031667407bcd984f2382480e8f12e832bc899c813c63974fbaeb6328ec1d1f6edbfefc70a9bc6ef5f4d07cc1928ecc8b2b90524635abbf"
    },
    {
      "line": 108,
      "relation": "association",
      "evidence": "Conversely, the most commonly associated symptoms of AD are cognitive in nature and include deficits in learning and memory. However, 50%–80% of AD patients display psychotic and behavioral disturbances that are correlated with poor social and functional outcomes",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 78,
      "target": 51,
      "key": "e864d5c9143b2aefa9ba3d8ef32fc7df2e741b194c29cd9f9a26ff3ab08d5491644324aaff4994bdc04a827058712cf7b7cb5f851b76b17da6b7204e763362e8"
    },
    {
      "line": 173,
      "relation": "decreases",
      "evidence": "AD is the most commonly diagnosed form of dementia and currently affects approximately 35 million individuals worldwide.7 AD is a progressive neurodegenerative disease that is characterized by a host of cognitive deficits, including impairments in learning and memory. In addition to the well-documented cognitive impairments, AD patients also display behavioral disturbances, including anxiety, depression, and psychosis",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 78,
      "target": 51,
      "key": "8422b906a27b7ec06e41135363ce09d9929cf3931f005fd13845bf30fb10b6c78048e45f2a803824229a95bc3a27486e1c5a66f8e4b019267bc5114abbeaf9f4"
    },
    {
      "line": 109,
      "relation": "association",
      "evidence": "Conversely, the most commonly associated symptoms of AD are cognitive in nature and include deficits in learning and memory. However, 50%–80% of AD patients display psychotic and behavioral disturbances that are correlated with poor social and functional outcomes",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 78,
      "target": 52,
      "key": "28233574c671dbac4921d54839386bdb70dc25f7393560b9253d9d02c321f7579ef56aab099915bf04a0a1ff85b312fdaafe9fc0ed8235d1824906947e1aaa68"
    },
    {
      "line": 174,
      "relation": "decreases",
      "evidence": "AD is the most commonly diagnosed form of dementia and currently affects approximately 35 million individuals worldwide.7 AD is a progressive neurodegenerative disease that is characterized by a host of cognitive deficits, including impairments in learning and memory. In addition to the well-documented cognitive impairments, AD patients also display behavioral disturbances, including anxiety, depression, and psychosis",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 78,
      "target": 52,
      "key": "814fdafba15e248ef8149e9ac2ee4f2efb9441362c83f586c329f8456c943a73d762a302b0b294babe4715ead893a7c28b1d87e4b3c2fa9dd9e1ae852f11e765"
    },
    {
      "line": 110,
      "relation": "association",
      "evidence": "Conversely, the most commonly associated symptoms of AD are cognitive in nature and include deficits in learning and memory. However, 50%–80% of AD patients display psychotic and behavioral disturbances that are correlated with poor social and functional outcomes",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 78,
      "target": 54,
      "key": "877356e3267429402fd029e7d769c6912cc2c2ca8ed08056ac9d18e3dfcd1d96c376a5949bbe111877d24e6eb888174edcbf8708e00b0fb0e74c03c9b532f560"
    },
    {
      "line": 117,
      "relation": "decreases",
      "evidence": "Another commonality between AD and SZ is the apparent involvement of dysregulated cholinergic signaling in the brain.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 78,
      "target": 47,
      "key": "f63be799eef75fee6a5a969bb63b576c2494ac347598b2a1b4a2bd3808d88b0c1c085fea2918a2b912c9c4261dcedce2a46d7729bf081fb9f9f68a267d6451a0"
    },
    {
      "line": 222,
      "relation": "decreases",
      "evidence": "1 Several lines of evidence suggest that impaired cholinergic signaling plays a key role in mediating both the cognitive and the behavioral impairments observed in AD patients.12 The basal forebrain cholinergic system is disproportionately affected in AD patients, with a robust loss of cholinergic neurons, including those innervating the hippocampus and cortex.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 78,
      "target": 47,
      "key": "154aa3756540b6b078183444d92d2b34a047ac2c62a9797f1c33b41ad10b4b6f1e05679363ae6c202e22159e3f7f743d68415e2cce55551e192e74bfb04a1942"
    },
    {
      "line": 170,
      "relation": "association",
      "evidence": "AD is the most commonly diagnosed form of dementia and currently affects approximately 35 million individuals worldwide.7 AD is a progressive neurodegenerative disease that is characterized by a host of cognitive deficits, including impairments in learning and memory. In addition to the well-documented cognitive impairments, AD patients also display behavioral disturbances, including anxiety, depression, and psychosis",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 78,
      "target": 93,
      "key": "3d9fb6548c0918fab494dc094cb7deb56165b6febf0cc6b12a34b091baea5ee5e9b9ca472dbd31e1b40ab51f7dbda65239372ded46e4e6349be55fe57377233e"
    },
    {
      "line": 171,
      "relation": "isA",
      "evidence": "AD is the most commonly diagnosed form of dementia and currently affects approximately 35 million individuals worldwide.7 AD is a progressive neurodegenerative disease that is characterized by a host of cognitive deficits, including impairments in learning and memory. In addition to the well-documented cognitive impairments, AD patients also display behavioral disturbances, including anxiety, depression, and psychosis",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 78,
      "target": 84,
      "key": "ae88ca4f9c01acbfdd0dbb0d6872e3347dcc0729ebc0bbfce55d726876677c229e09ce487739e75adf7de0f3b619b444b42de0d3e343c208d3341a10888b9de4"
    },
    {
      "line": 175,
      "relation": "increases",
      "evidence": "AD is the most commonly diagnosed form of dementia and currently affects approximately 35 million individuals worldwide.7 AD is a progressive neurodegenerative disease that is characterized by a host of cognitive deficits, including impairments in learning and memory. In addition to the well-documented cognitive impairments, AD patients also display behavioral disturbances, including anxiety, depression, and psychosis",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 78,
      "target": 94,
      "key": "482e142f101175a9b985906bdb38fed733ed4b774749861f75f8193b018b2fcbc26cd82c6571941501884d0f60786a79bdf13ba4e87c0e6291b56f7dc1e02de7"
    },
    {
      "line": 176,
      "relation": "increases",
      "evidence": "AD is the most commonly diagnosed form of dementia and currently affects approximately 35 million individuals worldwide.7 AD is a progressive neurodegenerative disease that is characterized by a host of cognitive deficits, including impairments in learning and memory. In addition to the well-documented cognitive impairments, AD patients also display behavioral disturbances, including anxiety, depression, and psychosis",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 78,
      "target": 90,
      "key": "beeaa00b584314706c77dc454eed70c7790e9d2d40f0418def1c75e4b497b44f884b73e03941911bc05f1d4eb8688c76367d3caddf09a96cb0c012dd3059f2a5"
    },
    {
      "line": 184,
      "relation": "association",
      "evidence": "Age is the primary risk factor for AD, and the disease usually manifests in individuals after the age of 60 years. Due to an aging population, the prevalence of AD is predicted to rise to 66 million people by the year 2030.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 78,
      "target": 57,
      "key": "16e2220f5e054057f9311988f0e63657fbe45269f42eb8c2ec6c63cf04acfa687ed667a3402a936f095c63fc8a9f3047928fb4ffcbf5cb9dfe9a9aebb23969e7"
    },
    {
      "line": 228,
      "relation": "decreases",
      "evidence": "1 Several lines of evidence suggest that impaired cholinergic signaling plays a key role in mediating both the cognitive and the behavioral impairments observed in AD patients.12 The basal forebrain cholinergic system is disproportionately affected in AD patients, with a robust loss of cholinergic neurons, including those innervating the hippocampus and cortex.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 78,
      "target": 27,
      "key": "fdd854a5f2424d8532ba7345bfef1a6920e92a9438ddf38bf30eccc84ec3d1d3c791bc415ab2ef39b12cf9bb0711944af99b547baeddbc422bfb8468c41047e6"
    },
    {
      "line": 85,
      "relation": "association",
      "evidence": "Schizophrenia (SZ) and Alzheimer’s disease (AD) are two devastating disorders of the central nervous system (CNS) that present clinically with cognitive impairments and psychotic symptoms",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true
        }
      },
      "source": 87,
      "target": 78,
      "key": "e44e45b89ec60845e582695b15a1da51308cd3a192281928b681dc81dc52c43856a74133f071febfb5d5fb01a4bb2b1375e899ba57d7d5049558db87d84a1ef9"
    },
    {
      "line": 111,
      "relation": "association",
      "evidence": "Conversely, the most commonly associated symptoms of AD are cognitive in nature and include deficits in learning and memory. However, 50%–80% of AD patients display psychotic and behavioral disturbances that are correlated with poor social and functional outcomes",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 87,
      "target": 78,
      "key": "e21219c2972968ba46ec43cc964437faf10679092f946af9fe397fa7255e903e29b5827ecabb71a41d8b343fa51590057d2e5ad4926c1b5bb6230693976ccda4"
    },
    {
      "line": 177,
      "relation": "association",
      "evidence": "AD is the most commonly diagnosed form of dementia and currently affects approximately 35 million individuals worldwide.7 AD is a progressive neurodegenerative disease that is characterized by a host of cognitive deficits, including impairments in learning and memory. In addition to the well-documented cognitive impairments, AD patients also display behavioral disturbances, including anxiety, depression, and psychosis",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 87,
      "target": 78,
      "key": "57f69c80f2fd45a416e7559aad4827471266a20a63358cdc70d4cd9ec478a06c493d71845fd36541e11a6b8177a5f29db685895d58b35c7136c2bedea4fefd6a"
    },
    {
      "line": 87,
      "relation": "association",
      "evidence": "Schizophrenia (SZ) and Alzheimer’s disease (AD) are two devastating disorders of the central nervous system (CNS) that present clinically with cognitive impairments and psychotic symptoms",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true
        }
      },
      "source": 87,
      "target": 96,
      "key": "b6d3c101f6a79957196a18a6c610e19a510314e1e29dd7c94abeb0a1612b0c3aaea5e2f616e12c4af07a105827a6fd70316b2c4933e0d538b1a13fd09171c417"
    },
    {
      "line": 86,
      "relation": "association",
      "evidence": "Schizophrenia (SZ) and Alzheimer’s disease (AD) are two devastating disorders of the central nervous system (CNS) that present clinically with cognitive impairments and psychotic symptoms",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true
        }
      },
      "source": 80,
      "target": 78,
      "key": "0bc7bbb511a590c755a05e96f9b3def6f4ac7a620550d9f31c8d397062893efb0be7fd82078b10ddf58f89f7acda7a426ed9acab49e7b4cf24da08bf827d69fe"
    },
    {
      "line": 172,
      "relation": "association",
      "evidence": "AD is the most commonly diagnosed form of dementia and currently affects approximately 35 million individuals worldwide.7 AD is a progressive neurodegenerative disease that is characterized by a host of cognitive deficits, including impairments in learning and memory. In addition to the well-documented cognitive impairments, AD patients also display behavioral disturbances, including anxiety, depression, and psychosis",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 80,
      "target": 78,
      "key": "789da1be2bd998301041bfa392092c39e995112396c7f1a3de1e707b7a2d13c202174106acf420badec1060d2304211408ed8c739fa2b3ac49fd6804dc4243f4"
    },
    {
      "line": 88,
      "relation": "association",
      "evidence": "Schizophrenia (SZ) and Alzheimer’s disease (AD) are two devastating disorders of the central nervous system (CNS) that present clinically with cognitive impairments and psychotic symptoms",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true
        }
      },
      "source": 80,
      "target": 96,
      "key": "3efa6b9c87f47c7d1cd93d185ea290da4d77e39f3373213ced91c308f2938b635a1b3773f4137f38a168d2ab43492b08dbfcbf5b104afd4ea3eba7459caee825"
    },
    {
      "line": 87,
      "relation": "association",
      "evidence": "Schizophrenia (SZ) and Alzheimer’s disease (AD) are two devastating disorders of the central nervous system (CNS) that present clinically with cognitive impairments and psychotic symptoms",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true
        }
      },
      "source": 96,
      "target": 87,
      "key": "3f860d1168223f767e6cdd7bf9ba9fc64f91d0e3bc2337013adedb11e7c8b8f607dd8ef78a812858bf5ecb59d204757fe7063188fa3b96d5a2afccebf418ff62"
    },
    {
      "line": 88,
      "relation": "association",
      "evidence": "Schizophrenia (SZ) and Alzheimer’s disease (AD) are two devastating disorders of the central nervous system (CNS) that present clinically with cognitive impairments and psychotic symptoms",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Central Nervous System": true
        }
      },
      "source": 96,
      "target": 80,
      "key": "3e439aee0813248dea31378fa5974da3b33485fae7f31aea081c75e93fdd5ccad04a7872989a4c83c7e11a80cf8f9472ddfff0680f0c8268c088a9de4567f67e"
    },
    {
      "line": 98,
      "relation": "association",
      "evidence": "Psychosis is the hallmark symptom of SZ and manifests as hallucinations, disordered thought/speech, and delusions. While these psychotic symptoms are commonly associated with SZ, it has become well documented that these patients also experience cognitive and behavioral disturbances that are not adequately addressed by currently prescribed typical and atypical psychotics.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 96,
      "target": 95,
      "key": "87c21f4a71bad33871125cf898a6da547610045d1a28e8878de611da318e3bf7618089af0762580f388d9a58d7f0a993c0f80c02d44f5e3bbe26071c5a60b556"
    },
    {
      "line": 99,
      "relation": "association",
      "evidence": "Psychosis is the hallmark symptom of SZ and manifests as hallucinations, disordered thought/speech, and delusions. While these psychotic symptoms are commonly associated with SZ, it has become well documented that these patients also experience cognitive and behavioral disturbances that are not adequately addressed by currently prescribed typical and atypical psychotics.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 96,
      "target": 92,
      "key": "6cfd6f46cdd68a7cf0c33f8876ed4085ddc184eb3408aa82ab9976a4642b54e2b3fbe264db2540751efba558f3c55d037ec0b88f6fd626451112f292c2955ef9"
    },
    {
      "line": 100,
      "relation": "association",
      "evidence": "Psychosis is the hallmark symptom of SZ and manifests as hallucinations, disordered thought/speech, and delusions. While these psychotic symptoms are commonly associated with SZ, it has become well documented that these patients also experience cognitive and behavioral disturbances that are not adequately addressed by currently prescribed typical and atypical psychotics.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 96,
      "target": 51,
      "key": "12559812d4075ae2c5427649a1fde0808d46a63294828f0aca63603a6210be535785353a9dad51aba6e4e72fac35951b8dd5ca9196cc8f372b2037fb640fcfc6"
    },
    {
      "line": 101,
      "relation": "association",
      "evidence": "Psychosis is the hallmark symptom of SZ and manifests as hallucinations, disordered thought/speech, and delusions. While these psychotic symptoms are commonly associated with SZ, it has become well documented that these patients also experience cognitive and behavioral disturbances that are not adequately addressed by currently prescribed typical and atypical psychotics.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 96,
      "target": 50,
      "key": "92a3dc6809e150b063997e2c6f698a001ba846d470de74105615cdae355ade1067fc99f72372173b5448d29f41de51ab9ca76e59139b3f335873300f40aadd5e"
    },
    {
      "line": 118,
      "relation": "decreases",
      "evidence": "Another commonality between AD and SZ is the apparent involvement of dysregulated cholinergic signaling in the brain.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 96,
      "target": 47,
      "key": "e1d813a10c82ca659965022c58d7d98c6f5e2ae3378d64c64da60571b130f5efe19a689ea13206ce510733db6b7bcffa6daf08039648ee0d311ffa60206da78e"
    },
    {
      "line": 311,
      "relation": "association",
      "evidence": "Accumulating evidence suggests that the three clusters of SZ symptoms cannot be ascribed solely to alterations in monoaminergic signaling as dysregulation of glutamatergic, gamma-aminobutyric acid (GABA)-ergic, and cholinergic systems have also been reported",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 96,
      "target": 47,
      "key": "8ccb98512b71d6764d589b0825f8638738c4ce247a31aaeba3170e84e59d2eb4568bd4ca44999f2e7baa4ce81d13527cdb1bfe4ef1f0b3606ce901c34c7843ed"
    },
    {
      "line": 288,
      "relation": "association",
      "evidence": "The hallmark psychotic symptoms of SZ are the positive cluster and include auditory hallucinations, delusional beliefs, and disorganized thoughts and speech. SZ patients also exhibit negative symptoms, including anhedonia, dysfunctional social interactions, and poverty of thoughts and speech, as well as cognitive disturbances affecting several behavioral domains, including working memory, attention, and executive function",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 96,
      "target": 82,
      "key": "11930fc5607aabbaa11baaff8fde337b839c8eaf17ff09152193d750f20d2f8ffa9ac34bc8d339e7bcc8e75de0994231d093a967492f086f001311ec80b4fbc5"
    },
    {
      "line": 289,
      "relation": "association",
      "evidence": "The hallmark psychotic symptoms of SZ are the positive cluster and include auditory hallucinations, delusional beliefs, and disorganized thoughts and speech. SZ patients also exhibit negative symptoms, including anhedonia, dysfunctional social interactions, and poverty of thoughts and speech, as well as cognitive disturbances affecting several behavioral domains, including working memory, attention, and executive function",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 96,
      "target": 91,
      "key": "0df93e0958f91ba9c0a9cd163e40746d4ae45cdde250304cd45ac307346154e0f4eab6485672db425e52a2879a1fe2e1b9182574ddb4ca3fda9b4eb1479b8c14"
    },
    {
      "line": 290,
      "relation": "association",
      "evidence": "The hallmark psychotic symptoms of SZ are the positive cluster and include auditory hallucinations, delusional beliefs, and disorganized thoughts and speech. SZ patients also exhibit negative symptoms, including anhedonia, dysfunctional social interactions, and poverty of thoughts and speech, as well as cognitive disturbances affecting several behavioral domains, including working memory, attention, and executive function",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 96,
      "target": 81,
      "key": "f3120fabf96f52af9ef4c9d31875cc6b90df039037f0eaf721b18420384751315cd8718031623002990fa9c92493a6e3398a65ec0c8e65bdcdfd6b1dc66180cc"
    },
    {
      "line": 312,
      "relation": "association",
      "evidence": "Accumulating evidence suggests that the three clusters of SZ symptoms cannot be ascribed solely to alterations in monoaminergic signaling as dysregulation of glutamatergic, gamma-aminobutyric acid (GABA)-ergic, and cholinergic systems have also been reported",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 96,
      "target": 49,
      "key": "de7a15946c32c97b30d931bbd0252c497bfbdb0e70049df05be6cc240a9a4f97e8b4d6c2856d79b1801e397139cd8e053ddf4c4ecabb28414324e5c6c7900575"
    },
    {
      "line": 313,
      "relation": "association",
      "evidence": "Accumulating evidence suggests that the three clusters of SZ symptoms cannot be ascribed solely to alterations in monoaminergic signaling as dysregulation of glutamatergic, gamma-aminobutyric acid (GABA)-ergic, and cholinergic systems have also been reported",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 96,
      "target": 44,
      "key": "11123b949d3b57b0a6b097bdb576df5dc3e3b70149d8e59f3c8af118bcff6e81e669154f804f25e5210fa35c0aadc59b2f6b05337bfac3710494f74c98eb4e3e"
    },
    {
      "line": 98,
      "relation": "association",
      "evidence": "Psychosis is the hallmark symptom of SZ and manifests as hallucinations, disordered thought/speech, and delusions. While these psychotic symptoms are commonly associated with SZ, it has become well documented that these patients also experience cognitive and behavioral disturbances that are not adequately addressed by currently prescribed typical and atypical psychotics.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 95,
      "target": 96,
      "key": "a54efd18ceff272b6b6108eca6598b8fdeacb8442bb7c29be1c182b62a328caf9f52a775d415805be80e3d25eeb357f241fa3a1a3c43ced6509747fff84bf6e6"
    },
    {
      "line": 284,
      "relation": "biomarkerFor",
      "evidence": "The hallmark psychotic symptoms of SZ are the positive cluster and include auditory hallucinations, delusional beliefs, and disorganized thoughts and speech. SZ patients also exhibit negative symptoms, including anhedonia, dysfunctional social interactions, and poverty of thoughts and speech, as well as cognitive disturbances affecting several behavioral domains, including working memory, attention, and executive function",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 95,
      "target": 96,
      "key": "39e1eebafc33fdff8e96e75e7c408a26dd16965066d2ef20553e8ed742b5807497ecc6c73e3049775c9e7564d552a946aa969d639b6028cdf0bc2001569a54cf"
    },
    {
      "line": 99,
      "relation": "association",
      "evidence": "Psychosis is the hallmark symptom of SZ and manifests as hallucinations, disordered thought/speech, and delusions. While these psychotic symptoms are commonly associated with SZ, it has become well documented that these patients also experience cognitive and behavioral disturbances that are not adequately addressed by currently prescribed typical and atypical psychotics.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 92,
      "target": 96,
      "key": "3922ad95a0cc2d553e6971add966b234f2faeffadb8fceee0e11a315e406c8158a8d4b0d1b0d75a11b5cf00fd83f3884ecb890f21be34354539253e161d5dc57"
    },
    {
      "line": 285,
      "relation": "biomarkerFor",
      "evidence": "The hallmark psychotic symptoms of SZ are the positive cluster and include auditory hallucinations, delusional beliefs, and disorganized thoughts and speech. SZ patients also exhibit negative symptoms, including anhedonia, dysfunctional social interactions, and poverty of thoughts and speech, as well as cognitive disturbances affecting several behavioral domains, including working memory, attention, and executive function",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 92,
      "target": 96,
      "key": "62d6ae51c6de2b94d2cb1558a7d981f7b829d46533e3c222fa1475bbca1a523c747d537d5ab73a7dd97875bde8b8a7925026aea3e0cccdeef76fa9a2efd8be12"
    },
    {
      "line": 100,
      "relation": "association",
      "evidence": "Psychosis is the hallmark symptom of SZ and manifests as hallucinations, disordered thought/speech, and delusions. While these psychotic symptoms are commonly associated with SZ, it has become well documented that these patients also experience cognitive and behavioral disturbances that are not adequately addressed by currently prescribed typical and atypical psychotics.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 51,
      "target": 96,
      "key": "c4b543a0c8812b849c0421af507bae213c72235d12682471fd4bb53afe002358d89d5b8f0c5c12bd4e4fcdfaadf959f110b480a045002cc411a918ae238ac8da"
    },
    {
      "line": 108,
      "relation": "association",
      "evidence": "Conversely, the most commonly associated symptoms of AD are cognitive in nature and include deficits in learning and memory. However, 50%–80% of AD patients display psychotic and behavioral disturbances that are correlated with poor social and functional outcomes",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 51,
      "target": 78,
      "key": "991d22d5b6e2a7358fd05ef0a382cb14c3028e5cc56d34870d41d32647369803904584085568eee3b8117f7e8ec5db54c88cfa895c3c59de5803201b821adf8a"
    },
    {
      "line": 205,
      "relation": "association",
      "evidence": "The popular amyloid cascade hypothesis posits that the gradual build-up of Abeta plaques leads to neuronal inflammation, dysfunction, and, eventually, cell death. The two brain regions most critically affected by this degeneration are the cortex and hippocampus, both of which are involved in cognition, learning, and memory.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 51,
      "target": 35,
      "key": "90e8d9814d9ee82b509c1e0ae99a7f0cd720ef88e534901eda46c5214318b789ea45287bd1c802be7441c974a6297e445b1c6b7501cb091ac93fa40230788b17"
    },
    {
      "line": 208,
      "relation": "association",
      "evidence": "The popular amyloid cascade hypothesis posits that the gradual build-up of Abeta plaques leads to neuronal inflammation, dysfunction, and, eventually, cell death. The two brain regions most critically affected by this degeneration are the cortex and hippocampus, both of which are involved in cognition, learning, and memory.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 51,
      "target": 26,
      "key": "0564d6b5c0ddf28417ffe52fb1896172e2653facd3d1abf4beebcbeaaf5e3ab7fc02b61eda81f01c73cfa70417517ee1b5b38f4d04fbdb2038e5a729e3425c64"
    },
    {
      "line": 223,
      "relation": "association",
      "evidence": "1 Several lines of evidence suggest that impaired cholinergic signaling plays a key role in mediating both the cognitive and the behavioral impairments observed in AD patients.12 The basal forebrain cholinergic system is disproportionately affected in AD patients, with a robust loss of cholinergic neurons, including those innervating the hippocampus and cortex.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 51,
      "target": 47,
      "key": "699fe8c453ccc0af0018315f6b565d5eb6ea21812b5447584365bbc796f66b39b906868bd12b505b009c89f4bdf2340483827d309179bb69ac050a4f2fc372be"
    },
    {
      "line": 366,
      "relation": "association",
      "evidence": "The M1 mAChR subtype is the most predominantly expressed mAChR subtype in the CNS and is expressed in several brain regions implicated in the regulation of cognitive processes, including the striatum, prefrontal cortex, and hippocampus.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Prefrontal Cortex": true,
          "Corpus Striatum": true
        }
      },
      "source": 51,
      "target": 65,
      "key": "cec7ce250378588e13e3a808a9d68201421237af5703b12a8102b9ffd3da551dca646e0ab1503b5cfcb3932e4af34c6ff57faa7905dc69dcb93a37318cc0ffaf"
    },
    {
      "line": 383,
      "relation": "association",
      "evidence": "N-methyl-D-aspartate (NMDA) receptors play a critical role in regulating synaptic plasticity, and disrupted NMDA-receptor neurotransmission is thought to underlie the cognitive deficits observed in numerous psychiatric diseases.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 51,
      "target": 75,
      "key": "5770bb6730011d9ddab73fcac642e0f3f9fe13e398c029753e2dd7933c19340a1d4ac8307a3d3eeec6f9c72652a500aafcf1efd2806573fe68bee4661e881927"
    },
    {
      "line": 492,
      "relation": "association",
      "evidence": "In brain slice electrophysiology studies, BQCA enhanced excitatory postsynaptic currents in medial prefrontal cortical neurons,69 an area critical for higher cognitive, learning, and memory functions.70 In pre-clinical animal studies, BQCA reversed scopolamine-impaired contextual fear conditioning and rescued medial prefrontal cortex-dependent discrimination reversal learning deficits in a transgenic mouse model of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Prefrontal Cortex": true
        }
      },
      "source": 51,
      "target": 33,
      "key": "a2e9131da3a5ef2df1713031dd919d391eb5b9dd8d3d81f0186d804422b3226db5bf4b554e962b2f5ccf418dc3fb19a2bd238819ce6129118994e5c6cb2460a4"
    },
    {
      "line": 101,
      "relation": "association",
      "evidence": "Psychosis is the hallmark symptom of SZ and manifests as hallucinations, disordered thought/speech, and delusions. While these psychotic symptoms are commonly associated with SZ, it has become well documented that these patients also experience cognitive and behavioral disturbances that are not adequately addressed by currently prescribed typical and atypical psychotics.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 50,
      "target": 96,
      "key": "c2455f468668d27cd1503f8cd4b490b5466187b0677f6d8ce8637aba0491b19ac0d72b961610b004fc54f9c301d012e2624ee0fd1062cc7c6af512acc45e445e"
    },
    {
      "line": 224,
      "relation": "association",
      "evidence": "1 Several lines of evidence suggest that impaired cholinergic signaling plays a key role in mediating both the cognitive and the behavioral impairments observed in AD patients.12 The basal forebrain cholinergic system is disproportionately affected in AD patients, with a robust loss of cholinergic neurons, including those innervating the hippocampus and cortex.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 50,
      "target": 47,
      "key": "ac2ad6a6a093270f6923cfd1f955d7e2e3fa291e35429e04d0a98db09d7804b3a725684f49f93de92c07c20a845db93e4b1c6e8f476fa00f5a3810466e0dc4c4"
    },
    {
      "line": 109,
      "relation": "association",
      "evidence": "Conversely, the most commonly associated symptoms of AD are cognitive in nature and include deficits in learning and memory. However, 50%–80% of AD patients display psychotic and behavioral disturbances that are correlated with poor social and functional outcomes",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 52,
      "target": 78,
      "key": "255f5ffc58ffafa9106a41569084fd59c3215667af7c7331cfe88d30ece9b588d1536ebf9116ba54efea550c2968a12e758d64fef36aa1e4d066f1c667e3fce5"
    },
    {
      "line": 206,
      "relation": "association",
      "evidence": "The popular amyloid cascade hypothesis posits that the gradual build-up of Abeta plaques leads to neuronal inflammation, dysfunction, and, eventually, cell death. The two brain regions most critically affected by this degeneration are the cortex and hippocampus, both of which are involved in cognition, learning, and memory.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 52,
      "target": 35,
      "key": "6e67eb118a7c345ad6fb7a0193779b0ff2ca388948f1ac9361b19f3807c4a06d4b8fc9c3e2071345a98aef075cf0d3752f338dcfd0ea9051b8da74cd0e4f314d"
    },
    {
      "line": 396,
      "relation": "association",
      "evidence": "M1 mAChRs have been demonstrated to potentiate NMDA-receptor signaling in the hippocampus and cortex,48,49 brain areas intimately associated with learning and memory. In addition, M1 KO mice displayed reduced hippocampal long-term potentiation, a mechanism heavily implicated in learning and memory. Behaviorally, M1 KO animals display deficits in several medial prefrontal cortex-dependent cognitive tasks, including non-matching-to- sample, win-shift radial arm maze, and social discrimination tasks.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 52,
      "target": 35,
      "key": "0c5b73100d4674070b541a7066844f014eb7f5f7615e1f3097a59c2e5391b9a31e17d99b2044f0c19492d82f59b2024e934892a11e49ae30e5d569f88346ff23"
    },
    {
      "line": 209,
      "relation": "association",
      "evidence": "The popular amyloid cascade hypothesis posits that the gradual build-up of Abeta plaques leads to neuronal inflammation, dysfunction, and, eventually, cell death. The two brain regions most critically affected by this degeneration are the cortex and hippocampus, both of which are involved in cognition, learning, and memory.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 52,
      "target": 26,
      "key": "0829ccf4586d4a940a8c0765390859275f35b7f4f1b1c70dfd72d34f087bcc453376298a9c5ff8bd35419da73fd4873251c0218b69c92b6695a312e95d5f81a6"
    },
    {
      "line": 398,
      "relation": "association",
      "evidence": "M1 mAChRs have been demonstrated to potentiate NMDA-receptor signaling in the hippocampus and cortex,48,49 brain areas intimately associated with learning and memory. In addition, M1 KO mice displayed reduced hippocampal long-term potentiation, a mechanism heavily implicated in learning and memory. Behaviorally, M1 KO animals display deficits in several medial prefrontal cortex-dependent cognitive tasks, including non-matching-to- sample, win-shift radial arm maze, and social discrimination tasks.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 52,
      "target": 26,
      "key": "eea061751f2f0981e6986e40d88969955bade46795f41eb43670cf23f98d50528ff4a7a014169fbdf1ef9f317323fb5bf2566db97b077b0d43e08a95dd4422fe"
    },
    {
      "line": 401,
      "relation": "association",
      "evidence": "M1 mAChRs have been demonstrated to potentiate NMDA-receptor signaling in the hippocampus and cortex,48,49 brain areas intimately associated with learning and memory. In addition, M1 KO mice displayed reduced hippocampal long-term potentiation, a mechanism heavily implicated in learning and memory. Behaviorally, M1 KO animals display deficits in several medial prefrontal cortex-dependent cognitive tasks, including non-matching-to- sample, win-shift radial arm maze, and social discrimination tasks.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 52,
      "target": 45,
      "key": "d700dc38bd166092d16364ea7758b915d2270fe64a4041d26e0ce6e5d2e6802d9b4f252b9aeb6e253311a64307caa79cc8a00d55fd00bd2dcfc30f56435b2287"
    },
    {
      "line": 493,
      "relation": "association",
      "evidence": "In brain slice electrophysiology studies, BQCA enhanced excitatory postsynaptic currents in medial prefrontal cortical neurons,69 an area critical for higher cognitive, learning, and memory functions.70 In pre-clinical animal studies, BQCA reversed scopolamine-impaired contextual fear conditioning and rescued medial prefrontal cortex-dependent discrimination reversal learning deficits in a transgenic mouse model of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Prefrontal Cortex": true
        }
      },
      "source": 52,
      "target": 33,
      "key": "31a1f36d01e44c8689ad5458639930203b54ddd3dd551f869ad6856de88adf556245262e3b0311ffae1c531ec7d82d6f14b8033ad490c076ebf85b4b342fdee6"
    },
    {
      "line": 110,
      "relation": "association",
      "evidence": "Conversely, the most commonly associated symptoms of AD are cognitive in nature and include deficits in learning and memory. However, 50%–80% of AD patients display psychotic and behavioral disturbances that are correlated with poor social and functional outcomes",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 54,
      "target": 78,
      "key": "c92f53de876b93feeae829880504e350f4401d3d992f5daf603cdc542f9d4cea504636abac4c98e46a78c9e9f2bb40d96deb4bb1117bb1780c8577d4dcc6b934"
    },
    {
      "line": 207,
      "relation": "association",
      "evidence": "The popular amyloid cascade hypothesis posits that the gradual build-up of Abeta plaques leads to neuronal inflammation, dysfunction, and, eventually, cell death. The two brain regions most critically affected by this degeneration are the cortex and hippocampus, both of which are involved in cognition, learning, and memory.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 54,
      "target": 35,
      "key": "0291742d20cadb02ff9d714cea82ec67b9460a8a18ca81da669e6c9e8612cdbdba131c26b5c8a3eef6e412bcf6e33e360d475dee15122f5eb1213ec878612829"
    },
    {
      "line": 397,
      "relation": "association",
      "evidence": "M1 mAChRs have been demonstrated to potentiate NMDA-receptor signaling in the hippocampus and cortex,48,49 brain areas intimately associated with learning and memory. In addition, M1 KO mice displayed reduced hippocampal long-term potentiation, a mechanism heavily implicated in learning and memory. Behaviorally, M1 KO animals display deficits in several medial prefrontal cortex-dependent cognitive tasks, including non-matching-to- sample, win-shift radial arm maze, and social discrimination tasks.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 54,
      "target": 35,
      "key": "9cae4e6f50e1b2508915a998fe04706451c5d8ae9bc941c1d4cc2152d24118096851e05c13205e874957721038ec27f6ce2a7fae8b9ee86f12980c0e55361d5d"
    },
    {
      "line": 210,
      "relation": "association",
      "evidence": "The popular amyloid cascade hypothesis posits that the gradual build-up of Abeta plaques leads to neuronal inflammation, dysfunction, and, eventually, cell death. The two brain regions most critically affected by this degeneration are the cortex and hippocampus, both of which are involved in cognition, learning, and memory.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 54,
      "target": 26,
      "key": "da7cb6d83eba96f386e1394075dfd6f0b68964c1800e15bacefad648fe0a60e99b49f10d7bdb9f462593a70e0f49bd025a9a1bae42ac029e836fbf41a94f68db"
    },
    {
      "line": 399,
      "relation": "association",
      "evidence": "M1 mAChRs have been demonstrated to potentiate NMDA-receptor signaling in the hippocampus and cortex,48,49 brain areas intimately associated with learning and memory. In addition, M1 KO mice displayed reduced hippocampal long-term potentiation, a mechanism heavily implicated in learning and memory. Behaviorally, M1 KO animals display deficits in several medial prefrontal cortex-dependent cognitive tasks, including non-matching-to- sample, win-shift radial arm maze, and social discrimination tasks.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 54,
      "target": 26,
      "key": "8c94b6d8986258f0f347165e93531b1336fe11287dd1b58a5b634b62a7b179f8ce926429cba69093f40d0ae63f57e6a592c6419a4037d133b8fa8ec8c8eec7e3"
    },
    {
      "line": 402,
      "relation": "association",
      "evidence": "M1 mAChRs have been demonstrated to potentiate NMDA-receptor signaling in the hippocampus and cortex,48,49 brain areas intimately associated with learning and memory. In addition, M1 KO mice displayed reduced hippocampal long-term potentiation, a mechanism heavily implicated in learning and memory. Behaviorally, M1 KO animals display deficits in several medial prefrontal cortex-dependent cognitive tasks, including non-matching-to- sample, win-shift radial arm maze, and social discrimination tasks.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 54,
      "target": 45,
      "key": "1081b21c5bde7a45c08a6c5015f2f5af2477fc31242f8fde69085395e1126da1366a1f869cefecf64025370eb199713379ee4ea5dc7abca285a2f9a6540dfcc8"
    },
    {
      "line": 494,
      "relation": "association",
      "evidence": "In brain slice electrophysiology studies, BQCA enhanced excitatory postsynaptic currents in medial prefrontal cortical neurons,69 an area critical for higher cognitive, learning, and memory functions.70 In pre-clinical animal studies, BQCA reversed scopolamine-impaired contextual fear conditioning and rescued medial prefrontal cortex-dependent discrimination reversal learning deficits in a transgenic mouse model of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Prefrontal Cortex": true
        }
      },
      "source": 54,
      "target": 33,
      "key": "c2aaf1a882eb7593b922026a84dbec481d33c7c4063c9b9777d366a7fce035cdc6f589cd4d53ba094815b9297162dca38ddbbe8fb4a3746e01f748b11228e290"
    },
    {
      "line": 223,
      "relation": "association",
      "evidence": "1 Several lines of evidence suggest that impaired cholinergic signaling plays a key role in mediating both the cognitive and the behavioral impairments observed in AD patients.12 The basal forebrain cholinergic system is disproportionately affected in AD patients, with a robust loss of cholinergic neurons, including those innervating the hippocampus and cortex.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 47,
      "target": 51,
      "key": "2c61c907f5135dba403e72b31073686c63e1bdacfc0ef079dea758f1cb582155c0df95722d6cb932726716ca8393c40c0897670d5dd2cd3dc8e148d8d3b07c12"
    },
    {
      "line": 224,
      "relation": "association",
      "evidence": "1 Several lines of evidence suggest that impaired cholinergic signaling plays a key role in mediating both the cognitive and the behavioral impairments observed in AD patients.12 The basal forebrain cholinergic system is disproportionately affected in AD patients, with a robust loss of cholinergic neurons, including those innervating the hippocampus and cortex.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 47,
      "target": 50,
      "key": "6bd7e1fc10f71e50d0b395538961ec15da310d7034e1df299fbb11ed2be63907ff24cd4dce67063902500323d1190ad1676f18e3346c40a835c398847a9b310f"
    },
    {
      "line": 311,
      "relation": "association",
      "evidence": "Accumulating evidence suggests that the three clusters of SZ symptoms cannot be ascribed solely to alterations in monoaminergic signaling as dysregulation of glutamatergic, gamma-aminobutyric acid (GABA)-ergic, and cholinergic systems have also been reported",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 47,
      "target": 96,
      "key": "c81e546476deb2fea6d7a47b324bbbd0b8f2ac569d43cf5aa07027c666f5aaea71f60b24d564b9105d465f6a989a6d1ba127975bd1d13274d146a9bdb4e87e07"
    },
    {
      "line": 130,
      "relation": "regulates",
      "evidence": "Acetylcholine (ACh) is a neurotransmitter that modulates neuronal function in several areas of the CNS associated with AD and/or SZ pathology, including the striatum, cortex, hippocampus, and prefrontal cortex.5 ACh mediates its actions via two families of receptors, termed the muscarinic ACh receptors (mAChRs) and the nicotinic ACh receptors (nAChRs).",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Prefrontal Cortex": true,
          "Cerebral Cortex": true,
          "Corpus Striatum": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 4,
      "target": 37,
      "key": "d527e3d62dec01231152d87eb7577620e2cdf1269791f0fcd5ab5426456f2cba4c77cbf108ef43d47698bb6d6868a938ef72de779d5bf77996d5f5a609ec30bc"
    },
    {
      "line": 554,
      "relation": "increases",
      "evidence": "Two novel M4-selective compounds, VU10010 and LY2033298, represented a breakthrough when they were described in 2008.84,85 VU10010 is a potent M4-selective PAM that increases affinity/efficacy of ACh to promote M4 mAChR activation.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 4,
      "target": 65,
      "key": "c6fdb66235a8991dd9d4ccfdbfbfb74c0f98cc49eef9282e17dc01188dbeac2e07af55cd1b6f66fce7479f01d0018459a2f641942d6f43c0920b4ed4d0ce046e"
    },
    {
      "line": 131,
      "relation": "regulates",
      "evidence": "Acetylcholine (ACh) is a neurotransmitter that modulates neuronal function in several areas of the CNS associated with AD and/or SZ pathology, including the striatum, cortex, hippocampus, and prefrontal cortex.5 ACh mediates its actions via two families of receptors, termed the muscarinic ACh receptors (mAChRs) and the nicotinic ACh receptors (nAChRs).",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Prefrontal Cortex": true,
          "Cerebral Cortex": true,
          "Corpus Striatum": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 73,
      "target": 4,
      "key": "e454f0119825d5e2f908c4686ad5c2543c874894622dd04787bc4720e5bde9410307acb9d897b598dbcab7869d5208e175a70d2b4e19c7e2d8af30f6cfc197e0"
    },
    {
      "relation": "hasMember",
      "source": 73,
      "target": 65,
      "key": "62dbefd014b2640be6054627159be5cd6d7f49059979324a714d72f58566624865f78a0121fbc73dfebf2fe3e0750081250d01fc838e8d918274ddcf18c89834"
    },
    {
      "relation": "hasMember",
      "source": 73,
      "target": 66,
      "key": "2b4bc8fce844a314bfb31519b1b7e13f79d8ca898451c95f286596103f910ff0d55a6191dad87decb361d9dc6aea3732cb11f669553deaf3865ecf776bb4e987"
    },
    {
      "relation": "hasMember",
      "source": 73,
      "target": 67,
      "key": "95817d2b8faba441748e658ebbe5322a1dcab234446a208819a41611ad3ab72b13ad154235ce432b6f6dbfc5433fd230bbcd648c1cae86525b57ffcee5c41c8a"
    },
    {
      "relation": "hasMember",
      "source": 73,
      "target": 68,
      "key": "7dc597e9afbc30a0465f961c7c3659b902599cef838ee83fadc12632d5901b97e84e0ffa2d283e579012b0addebac5394654371b32801b6c5d25e344edcb3fb4"
    },
    {
      "relation": "hasMember",
      "source": 73,
      "target": 69,
      "key": "8890538f3b9f954a65ac787c38690fd68e419e31e4a81e5a98651388808029641719b13df51a0901165045b715714d34bd36a6e8e55637dc5522388019a5b018"
    },
    {
      "line": 143,
      "relation": "isA",
      "evidence": "The mAChR family consists of five subtypes (M1 –M5) that can be found throughout the CNS and periphery. These receptors are guanosine nucleotide-binding protein (G-protein)-coupled receptors and can be subdivided based on their canonical signaling pathways.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 73,
      "target": 76,
      "key": "123c49c0791c0bf019fbfa75dabdfcc0f8c9987e8713f3d439025030bef91d876d3b049790766a4b3e0f901399492a8769953893785206dec1875648376f8bc1"
    },
    {
      "line": 242,
      "relation": "regulates",
      "evidence": " In addition, administration of nonselective muscarinic antagonists can produce or exacerbate cognitive deficits in animals,15 as well as in AD patients and both young and old control subjects,16,17 suggesting that mAChRs can directly modulate cognition.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 73,
      "target": 51,
      "key": "62a1cbe316abe61810cfba7a7562dddab9b86f6b93e0b7c10dd1350a486838dc151554c3b5b080ea21dbcaf1339a3b91be27559e04acebc1a39e98c0547e3414"
    },
    {
      "line": 132,
      "relation": "regulates",
      "evidence": "Acetylcholine (ACh) is a neurotransmitter that modulates neuronal function in several areas of the CNS associated with AD and/or SZ pathology, including the striatum, cortex, hippocampus, and prefrontal cortex.5 ACh mediates its actions via two families of receptors, termed the muscarinic ACh receptors (mAChRs) and the nicotinic ACh receptors (nAChRs).",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Prefrontal Cortex": true,
          "Cerebral Cortex": true,
          "Corpus Striatum": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 74,
      "target": 4,
      "key": "4c4dd9b40f8fbb84a623bf96960fd28f7ee0d82d19c1e3945d76f8dbbbd95a1b57c27cd321f54323df94c2b1034eee12cae6933a3ab25d801fe612df1b935d3b"
    },
    {
      "line": 366,
      "relation": "association",
      "evidence": "The M1 mAChR subtype is the most predominantly expressed mAChR subtype in the CNS and is expressed in several brain regions implicated in the regulation of cognitive processes, including the striatum, prefrontal cortex, and hippocampus.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Prefrontal Cortex": true,
          "Corpus Striatum": true
        }
      },
      "source": 65,
      "target": 51,
      "key": "bb6b6fd9ef686b434bd59ef9bde311ddb932079a127daa46cbffcdf606f95a68b98459bfebbe4fa361ce6f479cadc883f4ebb56c58a74ca4557c5878b7bd2f7b"
    },
    {
      "line": 427,
      "relation": "increases",
      "evidence": "Subsequent optimization produced two analogs of AC-42 (AC-260584 and 77-LH-28-1), which maintained M1 selectivity and possessed properties suitable for use in animal models. Both AC-260584 and 77-LH-28-1 displayed antipsychotic and cognition-enhancing efficacy in pre-clinical models",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 65,
      "target": 51,
      "key": "1a24e124b4053d2e610193464b2e1e5af0d2cb2c32631c7b3c96237543c96902a3108d6959a17034e80c1bd8c989f5d967a74d8a8e92b78eaa2e910babace8f9"
    },
    {
      "line": 374,
      "relation": "decreases",
      "evidence": "Interestingly, these M1-deficient mice display increased amphetamine-induced hyperlocomotion and dopamine neurotransmission,47 indicating that M1 modulation may have antipsychotic potential.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 65,
      "target": 5,
      "key": "8a1d54e60a8b98dbe88f80c1d888946bb2d07bcc1193890c1e2bff287fac4e73e2b8a68f9486b297921da353669ef7e49d86f923baf15be7ff16429225665cbc"
    },
    {
      "line": 375,
      "relation": "decreases",
      "evidence": "Interestingly, these M1-deficient mice display increased amphetamine-induced hyperlocomotion and dopamine neurotransmission,47 indicating that M1 modulation may have antipsychotic potential.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 65,
      "target": 42,
      "key": "a3fbc493259063824f1e627bfc53edf44b24d6805b8aac626e1e135ab9ef3dac6ad546ad06510d71f3df1160321318b11e0f2f49fdbede2cdfc66dfa5af3800c"
    },
    {
      "line": 395,
      "relation": "increases",
      "evidence": "M1 mAChRs have been demonstrated to potentiate NMDA-receptor signaling in the hippocampus and cortex,48,49 brain areas intimately associated with learning and memory. In addition, M1 KO mice displayed reduced hippocampal long-term potentiation, a mechanism heavily implicated in learning and memory. Behaviorally, M1 KO animals display deficits in several medial prefrontal cortex-dependent cognitive tasks, including non-matching-to- sample, win-shift radial arm maze, and social discrimination tasks.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 65,
      "target": 75,
      "key": "0f0425a9e8ec1cf51a217a3ddf4dc5c62512db8cc99a8ea8f9c95eb031c401f8f12a81583a07650681ddb1ff74c01abe0abae5982d94b9050cd6f2a87f7f94ca"
    },
    {
      "line": 437,
      "relation": "increases",
      "evidence": "Another early allosteric agonist, TBPB (1-(1’-(2-methylbenzyl) -1,4’-bipiperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-1), also exhibited impressive selectivity for M1 mAChRs and potentiated NMDA receptor currents in CA1 hippocampal cells. ",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "CA1 Region, Hippocampal": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 65,
      "target": 75,
      "key": "55f7ce4d530a0161df4b25dfdf3342dacc5ea39a6c504c0b8327b0ecddde134283a0ae914566b58f9bfcb0d48a10aeaea65abda0a3921f5fed9ec6e0f76e43ea"
    },
    {
      "line": 400,
      "relation": "increases",
      "evidence": "M1 mAChRs have been demonstrated to potentiate NMDA-receptor signaling in the hippocampus and cortex,48,49 brain areas intimately associated with learning and memory. In addition, M1 KO mice displayed reduced hippocampal long-term potentiation, a mechanism heavily implicated in learning and memory. Behaviorally, M1 KO animals display deficits in several medial prefrontal cortex-dependent cognitive tasks, including non-matching-to- sample, win-shift radial arm maze, and social discrimination tasks.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 65,
      "target": 45,
      "key": "64cbea9e11b58e36060051d4b8a0f216ec56e91050235a1f75b0d49254a370fc83e16ddd14962713da088f9023f144e58ae3a1305b2ea2e858a5eaf79fcb9889"
    },
    {
      "line": 479,
      "relation": "increases",
      "evidence": "The first subtype-selective M1 PAM to be characterized was benzyl quinolone carboxylic acid (BQCA);68 BQCA exhibited high selectivity with no activity at mAChR subtypes M2–M5 and induced up to a 129-fold leftward shift in ACh potency at the M1 mAChR",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 65,
      "target": 4,
      "key": "c14a9e658f2a134634e5f8f3f73a78db3822cd0b7e8579dcbc80ebe699a87309e962eab6c2628fd11de8ffce975a4875ec98395ee73e3ed0dd167a714dbe46e5"
    },
    {
      "line": 523,
      "relation": "increases",
      "evidence": "Recent drug discovery efforts in our group have yielded novel M1-selective PAMs VU0405652 (ML169) and VU0456940, both of which potentiate M1-mediated non-amyloidogenic amyloid precursor protein (APPsalpha) processing, suggesting disease-modifying potential in AD",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Degradation"
      },
      "source": 65,
      "target": 14,
      "key": "abc52b5f4d386e9793ae26f2b305719c1a808f038bf499e601bd6ae0861af1ae29a8243b2bf4734f5e65cffcb045c82b9f8fb871bcd9c9c87864c49dce82e1f3"
    },
    {
      "line": 535,
      "relation": "association",
      "evidence": "Conversely, the nonselective mAChR agonist BuTAC ([5R-(exo)]-6-[4-butylthio-1,2,5-thiadiazol-3-yl]-1-azabicyclo-[3.2.1]-octane) shows an antipsychotic profile when tested in numerous preclinical animal models. Administration of BuTAC reduces apomorphine-induced climbing and apomorphine-induced disruptions of prepulse inhibition78,79 and reduces conditioned avoidance responding in wild-type, but not M4 KO mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 68,
      "target": 79,
      "key": "14a3657b91bac02ea939996066b21e22f0460487e5c5c4221bb844bac9f9e0d8630f960ef4e5c41443303246c78e0fd5b55473320b0697391a815929a7d67036"
    },
    {
      "line": 543,
      "relation": "association",
      "evidence": "The M4 receptor is highly expressed in the striatum, hippocampus, and neocortex,45,46 suggesting that this mAChR subtype is ideally located to modulate dopaminergic signaling. In support of this hypothesis, M4 KO mice exhibit a hyperdopaminergic phenotype that is resistant to mAChR agonist-induced attenuation of dopamine levels.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 68,
      "target": 35,
      "key": "69506cfe109953ebef15b56c02dbd5056891f69d6aeeb2ad34d8e23296bcbf62f478aabac84b4066197dfb10ac30af3cf16837c9b49c874ecbf9039d8bf50eb7"
    },
    {
      "line": 544,
      "relation": "association",
      "evidence": "The M4 receptor is highly expressed in the striatum, hippocampus, and neocortex,45,46 suggesting that this mAChR subtype is ideally located to modulate dopaminergic signaling. In support of this hypothesis, M4 KO mice exhibit a hyperdopaminergic phenotype that is resistant to mAChR agonist-induced attenuation of dopamine levels.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 68,
      "target": 28,
      "key": "a3d62d00ebf358fc53e1c5fb8c8fb0eb6155e3b2cc7e69221ecfd614ea6cb4aeb0756343d27905d125468b0cc05a7211de7cfdaccb1d0c80f7776f79e0ead83e"
    },
    {
      "line": 545,
      "relation": "association",
      "evidence": "The M4 receptor is highly expressed in the striatum, hippocampus, and neocortex,45,46 suggesting that this mAChR subtype is ideally located to modulate dopaminergic signaling. In support of this hypothesis, M4 KO mice exhibit a hyperdopaminergic phenotype that is resistant to mAChR agonist-induced attenuation of dopamine levels.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 68,
      "target": 36,
      "key": "d8cbfc37229ea79b3dc852d41f885ea902b1a42f3d18b352b50795b0f65e34fb388fc031dca2622130b4a97d7d4373861ba9f0e5a66120aecb45b4140e3cedd1"
    },
    {
      "line": 546,
      "relation": "regulates",
      "evidence": "The M4 receptor is highly expressed in the striatum, hippocampus, and neocortex,45,46 suggesting that this mAChR subtype is ideally located to modulate dopaminergic signaling. In support of this hypothesis, M4 KO mice exhibit a hyperdopaminergic phenotype that is resistant to mAChR agonist-induced attenuation of dopamine levels.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 68,
      "target": 48,
      "key": "1f5c134b3ab904dde4787211671308b97c5872e6bdc1e7be6f1f0b5eb8f6de5d756235a12d397dd11513ebf0e9ce80d608c1302b8034474ada9e150cede2bdf4"
    },
    {
      "line": 564,
      "relation": "decreases",
      "evidence": "In brain slices, VU10010 selectively potentiated mAChR-mediated reductions in glutamatergic, but not GABAergic, signaling in hippocampal neurons, indicating a key role for M4 in regulating hippocampal function, and possibly in modulating cognition.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 68,
      "target": 49,
      "key": "42b93ee6b034b20b5d7e65543c93913b0950c07dd5aa08a171802fe6cebe1df2c16bafa528c29cf126469b7afb5881b799c62f39bfebcb7ad2c4778d963365ba"
    },
    {
      "relation": "hasComponent",
      "source": 60,
      "target": 65,
      "key": "1478721a04c1dd28efd780dd2ea2290d3da9b90d874034945814cf5e37390bcca35cbe045ce885158e8907b6e3b4321f7911501147b41220e9e4c65827678b1a"
    },
    {
      "relation": "hasComponent",
      "source": 60,
      "target": 72,
      "key": "53e4fb6a228d0427da5853adf42fead9931abd27aa56729e70f485a7a6fd31de961b9b12b3b20b404cc48b4e5a7e116db765a92a4532c084c9d8ab1a861d0ad8"
    },
    {
      "line": 151,
      "relation": "increases",
      "evidence": "M1, M3, and M5 all signal primarily via the Galphaq G-protein and induce Ca2+ mobilization and inositol trisphosphate (IP3) production, while M2 and M4 signal via the Galphai G-protein to inhibit cyclic adenosine monophosphate (cAMP) production.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 60,
      "target": 40,
      "key": "126b7a4d2f56e86662828af3b1385c4a51fe92c4fa2df6fcd6e1b90aa94c2471db8fae7473ca0951647c5581ef52c63f9aedca33ece3427fa64990b27259d634"
    },
    {
      "line": 152,
      "relation": "increases",
      "evidence": "M1, M3, and M5 all signal primarily via the Galphaq G-protein and induce Ca2+ mobilization and inositol trisphosphate (IP3) production, while M2 and M4 signal via the Galphai G-protein to inhibit cyclic adenosine monophosphate (cAMP) production.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 60,
      "target": 31,
      "key": "b474ec2ce3e99e43c816dca80737e0e82aa185bc45e2800746788469caeb96baab950c4440b0b2c8d0795f080c283e227a9a5cc49ca2ce9ac6ecd8d258e57863"
    },
    {
      "relation": "hasComponent",
      "source": 62,
      "target": 67,
      "key": "0a605d62535c7f4f05e69798e1ba838ae01b677dd0d56797c183300c7bffa5b60eb0632f12e8dc5389f662e27a1f5bddba9110dc433aa731f777a41e805f7e5b"
    },
    {
      "relation": "hasComponent",
      "source": 62,
      "target": 72,
      "key": "79d55c7af50950017cabe3ee4622728ec9a639f1cb9730a018d4d1a70bd2cefb8f2f388010bda9a92e0df8d558db66cd6403aa69764e1168ff04e2346aba52ca"
    },
    {
      "line": 153,
      "relation": "increases",
      "evidence": "M1, M3, and M5 all signal primarily via the Galphaq G-protein and induce Ca2+ mobilization and inositol trisphosphate (IP3) production, while M2 and M4 signal via the Galphai G-protein to inhibit cyclic adenosine monophosphate (cAMP) production.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 62,
      "target": 40,
      "key": "370de61e040b52f478f407d6927154329385453866442a7a56556a7703c84919078fc34e27e543a3cb861ff8f0325f946118f4223da79151d044fb0e82399e2e"
    },
    {
      "line": 154,
      "relation": "increases",
      "evidence": "M1, M3, and M5 all signal primarily via the Galphaq G-protein and induce Ca2+ mobilization and inositol trisphosphate (IP3) production, while M2 and M4 signal via the Galphai G-protein to inhibit cyclic adenosine monophosphate (cAMP) production.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 62,
      "target": 31,
      "key": "80e3a9dcf0175fea431463dbf73076c16803350c02dae78feb99989e57e1adae9d10c96bb323e3b7d213acb5a9063c0d54f864d8389800c7d5f4cbf7721cdc59"
    },
    {
      "relation": "hasComponent",
      "source": 64,
      "target": 69,
      "key": "fff4e56c71af1aa5cf384225fd0331ea05f214d3fdd8c74075e65c5b08111be91031fb69fd0a09c681d1d71a0e77ac038efd47f144fb9f1f0e7fc5575773b542"
    },
    {
      "relation": "hasComponent",
      "source": 64,
      "target": 72,
      "key": "c9b4cda602c60f51d27ae924c5eca62e5ce2376e1bed1ac29480fcae3c1416e2b35eed8e51c5b637fbeda937942c925b42cb559d1a048ea767cf6556ff5785c9"
    },
    {
      "line": 155,
      "relation": "increases",
      "evidence": "M1, M3, and M5 all signal primarily via the Galphaq G-protein and induce Ca2+ mobilization and inositol trisphosphate (IP3) production, while M2 and M4 signal via the Galphai G-protein to inhibit cyclic adenosine monophosphate (cAMP) production.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 64,
      "target": 40,
      "key": "04278e34439c68241c15394126ec1c093bdbd2aa36b8f7e11248113d2ef650093e66e6db20daef84284a6880c3e2303a7f3f997ab5241cf48fb4b5bf5c086e76"
    },
    {
      "line": 156,
      "relation": "increases",
      "evidence": "M1, M3, and M5 all signal primarily via the Galphaq G-protein and induce Ca2+ mobilization and inositol trisphosphate (IP3) production, while M2 and M4 signal via the Galphai G-protein to inhibit cyclic adenosine monophosphate (cAMP) production.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 64,
      "target": 31,
      "key": "7da16d8042cc15fd8f824c5cd6beb088dcd9d4b8b03d95aac18bdb8c4b09993b4d88d0a1bbaaf90211f41d65539f0a3da3bdd5b8677b2d4c1cb1a1c9f205b23d"
    },
    {
      "relation": "hasComponent",
      "source": 61,
      "target": 66,
      "key": "d3c81bda5130d70403e667d7ea0239426fbe2a66b7dde3518222944fd5225844af1d7553dccaeff3496c324696652a4d94acdac1cda7dfec2138d19af01f3563"
    },
    {
      "relation": "hasComponent",
      "source": 61,
      "target": 71,
      "key": "e19981590e1bee77f68582a151d3a6aa7eecbe3f64616ffe0f50aa468373b2fa03cdb7c87b618ce114df44a915253afaba68efef0eaa1ebe670ee400bc8b39e3"
    },
    {
      "line": 157,
      "relation": "decreases",
      "evidence": "M1, M3, and M5 all signal primarily via the Galphaq G-protein and induce Ca2+ mobilization and inositol trisphosphate (IP3) production, while M2 and M4 signal via the Galphai G-protein to inhibit cyclic adenosine monophosphate (cAMP) production.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 61,
      "target": 0,
      "key": "25082a62bb1d7ca5b7efd9e02ad0079b544e8ce12cef64cfeea8e729adb08b4f316a051c92e3218ae9d9d55273d1e3f935fd8598e75d2a8e4ceb2901bd56bd4a"
    },
    {
      "relation": "hasComponent",
      "source": 63,
      "target": 68,
      "key": "55e8d23f435badeaa448c4e443b2c12cf0610a43127289d33382c19d3ad16adc7a28dc70bdf8413dc7a0174341ac1b4cb01c9395e63a8a7cf89cc3a07c49dde5"
    },
    {
      "relation": "hasComponent",
      "source": 63,
      "target": 71,
      "key": "b8bdb483d3d692c2815b52b0fc7e52b285814afabf6bfcbf45683ee2f256753b18bc459d608687ff2db6ccb12741b7b3f0021180bca6b6ed183c8730a3560812"
    },
    {
      "line": 158,
      "relation": "decreases",
      "evidence": "M1, M3, and M5 all signal primarily via the Galphaq G-protein and induce Ca2+ mobilization and inositol trisphosphate (IP3) production, while M2 and M4 signal via the Galphai G-protein to inhibit cyclic adenosine monophosphate (cAMP) production.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 63,
      "target": 0,
      "key": "d6e7b9e298894212974cc30f21d4c7aa9438c6c6276c8751bb29006cc220121f22eebaeec6bda4583950ff7f6c3c449a2d6e46d5f3ca7f75a26cc74fd4666161"
    },
    {
      "line": 170,
      "relation": "association",
      "evidence": "AD is the most commonly diagnosed form of dementia and currently affects approximately 35 million individuals worldwide.7 AD is a progressive neurodegenerative disease that is characterized by a host of cognitive deficits, including impairments in learning and memory. In addition to the well-documented cognitive impairments, AD patients also display behavioral disturbances, including anxiety, depression, and psychosis",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 93,
      "target": 78,
      "key": "ec5e3d5c6a4b3aad3aa8c2169ec1df8b785b4d0fe7a5ef39bfeb5b4d1ad1155b58ab1b74865ae7f269db1b5f4144465e20cdda061916426c0af840a7b96875a2"
    },
    {
      "line": 184,
      "relation": "association",
      "evidence": "Age is the primary risk factor for AD, and the disease usually manifests in individuals after the age of 60 years. Due to an aging population, the prevalence of AD is predicted to rise to 66 million people by the year 2030.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 57,
      "target": 78,
      "key": "069cec21c915091890faf7987661072112378ef6d4e5b8aee22a7f3903ed3463d0cec3e1ec7a2469709be4346f72b7e2bcbdbff4566cac380ea4cb859537c5cc"
    },
    {
      "line": 190,
      "relation": "association",
      "evidence": "The hallmarks of AD pathology are the accumulation of amyloid-beta (Abeta) peptide aggregates (neuritic plaques) and hyperphosphorylated tau protein (neurofibrillary tangles).",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 13,
      "target": 86,
      "key": "62f88019cdcef755534397c70453624c3f5bbf20b6d3d83634b3aac51f804a53664a10745c8cb4df55eaeffffa65014dae437b2bd02ccecce45e3e3609a47280"
    },
    {
      "line": 190,
      "relation": "association",
      "evidence": "The hallmarks of AD pathology are the accumulation of amyloid-beta (Abeta) peptide aggregates (neuritic plaques) and hyperphosphorylated tau protein (neurofibrillary tangles).",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 86,
      "target": 13,
      "key": "c91fc44cab118e019268305d30817942ef9c65a693e0508a3ef9ff75bc3e80b755b6b08fb7e4d22771cca602dff460813c27c19ddd8fce83934df9a7045ba668"
    },
    {
      "line": 191,
      "relation": "biomarkerFor",
      "evidence": "The hallmarks of AD pathology are the accumulation of amyloid-beta (Abeta) peptide aggregates (neuritic plaques) and hyperphosphorylated tau protein (neurofibrillary tangles).",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 86,
      "target": 78,
      "key": "be67ab42000edae499469b4d4223605271a0e6b13ecf99620bcdce463fe744ea9031e0ab90a964d8529c056695a318b36a0175c5c634f9268512fabf99cebaea"
    },
    {
      "line": 203,
      "relation": "increases",
      "evidence": "The popular amyloid cascade hypothesis posits that the gradual build-up of Abeta plaques leads to neuronal inflammation, dysfunction, and, eventually, cell death. The two brain regions most critically affected by this degeneration are the cortex and hippocampus, both of which are involved in cognition, learning, and memory.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 86,
      "target": 55,
      "key": "ef18f017cbe5952c66b00930c4d17a1099d30e60881aa75804010abea74fae3ba90685d3a5caf92f62d3f1473d95c831761fd6c3d947a6752b6f1676bedd4dd6"
    },
    {
      "line": 204,
      "relation": "increases",
      "evidence": "The popular amyloid cascade hypothesis posits that the gradual build-up of Abeta plaques leads to neuronal inflammation, dysfunction, and, eventually, cell death. The two brain regions most critically affected by this degeneration are the cortex and hippocampus, both of which are involved in cognition, learning, and memory.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 86,
      "target": 41,
      "key": "506dc7333a853d23608901c43c77a71b727d8260863c116d2fe7d2a11d69af4fbb4b1512c273412c9b3f79ae4bd09f7687dcb87a81e6d51217e8a52d64784735"
    },
    {
      "line": 192,
      "relation": "biomarkerFor",
      "evidence": "The hallmarks of AD pathology are the accumulation of amyloid-beta (Abeta) peptide aggregates (neuritic plaques) and hyperphosphorylated tau protein (neurofibrillary tangles).",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 85,
      "target": 78,
      "key": "2074756079ce91297347258397de20dd2e188f384d9619590153c875e44417bad8e25702e57940f7f83c267e3409a2c2e172216f06afaf1edac38e0317429158"
    },
    {
      "line": 205,
      "relation": "association",
      "evidence": "The popular amyloid cascade hypothesis posits that the gradual build-up of Abeta plaques leads to neuronal inflammation, dysfunction, and, eventually, cell death. The two brain regions most critically affected by this degeneration are the cortex and hippocampus, both of which are involved in cognition, learning, and memory.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 35,
      "target": 51,
      "key": "84a4d88cea798b4686055e42d255fa1cf6b9f42e29370cd88fce66aea732748e5d8b35863a4aafe69d2726dad9d7ddc7a4152dbc5d2e0f816634147897bd557c"
    },
    {
      "line": 206,
      "relation": "association",
      "evidence": "The popular amyloid cascade hypothesis posits that the gradual build-up of Abeta plaques leads to neuronal inflammation, dysfunction, and, eventually, cell death. The two brain regions most critically affected by this degeneration are the cortex and hippocampus, both of which are involved in cognition, learning, and memory.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 35,
      "target": 52,
      "key": "8cc1db0bbd5ba94073147dadc2523dae01bf2012be478002b1b4341d37dea756dcd0cc54c2ff9cd7c55be7b6c90597d37761eec48f0a9f4953c4cf31ac9a14f3"
    },
    {
      "line": 396,
      "relation": "association",
      "evidence": "M1 mAChRs have been demonstrated to potentiate NMDA-receptor signaling in the hippocampus and cortex,48,49 brain areas intimately associated with learning and memory. In addition, M1 KO mice displayed reduced hippocampal long-term potentiation, a mechanism heavily implicated in learning and memory. Behaviorally, M1 KO animals display deficits in several medial prefrontal cortex-dependent cognitive tasks, including non-matching-to- sample, win-shift radial arm maze, and social discrimination tasks.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 35,
      "target": 52,
      "key": "883dd2c79c9dd9d562e787810ba31a64b353bdd89db8e7d83570ed245daa8275fdf9d3d5d63553bfda8f35f913a1dcdf601433e649116773c482f8e690b12d08"
    },
    {
      "line": 207,
      "relation": "association",
      "evidence": "The popular amyloid cascade hypothesis posits that the gradual build-up of Abeta plaques leads to neuronal inflammation, dysfunction, and, eventually, cell death. The two brain regions most critically affected by this degeneration are the cortex and hippocampus, both of which are involved in cognition, learning, and memory.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 35,
      "target": 54,
      "key": "66168d98f41fba8b878946e8a2bfbfa4b9ca0ac5916485ac000259f3841cf7fc46018859c74483d5953c614a6c44b231728cfd754c2f266160c080ceaa5472af"
    },
    {
      "line": 397,
      "relation": "association",
      "evidence": "M1 mAChRs have been demonstrated to potentiate NMDA-receptor signaling in the hippocampus and cortex,48,49 brain areas intimately associated with learning and memory. In addition, M1 KO mice displayed reduced hippocampal long-term potentiation, a mechanism heavily implicated in learning and memory. Behaviorally, M1 KO animals display deficits in several medial prefrontal cortex-dependent cognitive tasks, including non-matching-to- sample, win-shift radial arm maze, and social discrimination tasks.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 35,
      "target": 54,
      "key": "2facbbe0152657431ec2121bde80db94b3b4c4035d86538f157739d8b2f3401f18fa9f5a7e30e308b8d1353c10400466a316a62c87862b1894e65cd9557a5b84"
    },
    {
      "line": 543,
      "relation": "association",
      "evidence": "The M4 receptor is highly expressed in the striatum, hippocampus, and neocortex,45,46 suggesting that this mAChR subtype is ideally located to modulate dopaminergic signaling. In support of this hypothesis, M4 KO mice exhibit a hyperdopaminergic phenotype that is resistant to mAChR agonist-induced attenuation of dopamine levels.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 35,
      "target": 68,
      "key": "1a2e89c38423f92d92db2404f12ec5ae2a69b78f5a9eee46a279c496695d3a64af64bbf4570173e741590459ae5361417bd9ddbf8aa0df0cf7d67168e3b4a5b4"
    },
    {
      "line": 208,
      "relation": "association",
      "evidence": "The popular amyloid cascade hypothesis posits that the gradual build-up of Abeta plaques leads to neuronal inflammation, dysfunction, and, eventually, cell death. The two brain regions most critically affected by this degeneration are the cortex and hippocampus, both of which are involved in cognition, learning, and memory.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 26,
      "target": 51,
      "key": "c9c1bee841e4a946d90122935ad81d33b63a69eeb05941f5d531a267d4921985713bf581a42f82c3b363d9705dca248e22dda5cab6bf53d2fa0b4d6216e3dca4"
    },
    {
      "line": 209,
      "relation": "association",
      "evidence": "The popular amyloid cascade hypothesis posits that the gradual build-up of Abeta plaques leads to neuronal inflammation, dysfunction, and, eventually, cell death. The two brain regions most critically affected by this degeneration are the cortex and hippocampus, both of which are involved in cognition, learning, and memory.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 26,
      "target": 52,
      "key": "44ae0ac0cbf141fc7d9611402bb764b860c58b38f84d7b886816a2650d7aa78fe4f41bfb9f757d37ba5661739349ba4c9e40a93e1555b3bf343acdab78583e35"
    },
    {
      "line": 398,
      "relation": "association",
      "evidence": "M1 mAChRs have been demonstrated to potentiate NMDA-receptor signaling in the hippocampus and cortex,48,49 brain areas intimately associated with learning and memory. In addition, M1 KO mice displayed reduced hippocampal long-term potentiation, a mechanism heavily implicated in learning and memory. Behaviorally, M1 KO animals display deficits in several medial prefrontal cortex-dependent cognitive tasks, including non-matching-to- sample, win-shift radial arm maze, and social discrimination tasks.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 26,
      "target": 52,
      "key": "7ce09cd44fef3aaa37c684f5d107893d399e2258cec9156fe60ccb50d171a85803bcb2d25563803269a2e48a717954222b9b2c543da41df78fd266b287bea835"
    },
    {
      "line": 210,
      "relation": "association",
      "evidence": "The popular amyloid cascade hypothesis posits that the gradual build-up of Abeta plaques leads to neuronal inflammation, dysfunction, and, eventually, cell death. The two brain regions most critically affected by this degeneration are the cortex and hippocampus, both of which are involved in cognition, learning, and memory.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 26,
      "target": 54,
      "key": "0ea15586d6e583ae6fd9ce0173f8a27731bfa23f01b43a39f4ba178db7791aa7b6c0e4213d9eb0164f7a019c82bb7c5e8d092e95eea5fed6d25f9ad3628fd508"
    },
    {
      "line": 399,
      "relation": "association",
      "evidence": "M1 mAChRs have been demonstrated to potentiate NMDA-receptor signaling in the hippocampus and cortex,48,49 brain areas intimately associated with learning and memory. In addition, M1 KO mice displayed reduced hippocampal long-term potentiation, a mechanism heavily implicated in learning and memory. Behaviorally, M1 KO animals display deficits in several medial prefrontal cortex-dependent cognitive tasks, including non-matching-to- sample, win-shift radial arm maze, and social discrimination tasks.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 26,
      "target": 54,
      "key": "31141218582265b9ccf8027791cc142f5f377e620022306ea9a086d942d65268f93c7798d858295c40de91ee053bf3a35b1b282639197cfddfe8f53b2da136ad"
    },
    {
      "line": 241,
      "relation": "decreases",
      "evidence": " In addition, administration of nonselective muscarinic antagonists can produce or exacerbate cognitive deficits in animals,15 as well as in AD patients and both young and old control subjects,16,17 suggesting that mAChRs can directly modulate cognition.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 32,
      "target": 51,
      "key": "80800b8714626034da15a8d738157c51a69da78d908bc1dc1b80c1aef87fd2960a6b30e77f0c3d48ecfaec252cf7881ef664e823919e262dafa3e5c07cc79577"
    },
    {
      "line": 320,
      "relation": "increases",
      "evidence": "Furthermore, administration of nonselective muscarinic antagonists can induce cognitive deficits and psychosis in humans,16,37 indicating that mAChR activation may provide pro-cognitive and antipsychotic efficacy.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 32,
      "target": 80,
      "key": "89e8840bac0b2293b8018a868114d612c4cb8362df9db73cc80c3361344c66303597c2c3b7ef2925592b933011b48cc75455d0ad66e9112a1c2a947559735abd"
    },
    {
      "line": 321,
      "relation": "association",
      "evidence": "Furthermore, administration of nonselective muscarinic antagonists can induce cognitive deficits and psychosis in humans,16,37 indicating that mAChR activation may provide pro-cognitive and antipsychotic efficacy.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 32,
      "target": 83,
      "key": "b165bc1c0268bd2ef515e906da9ba6dcfb6cbc0980e3c4d937977fea5e52ae98bba33f68e2388fb1a638691f64dcd6c2c5d9c5e09557280129e905e344b056f8"
    },
    {
      "line": 256,
      "relation": "isA",
      "evidence": "The current primary treatments for AD symptoms are acetylcholinesterase inhibitors (AChEIs) such as donepezil, tacrine, galantamine, and rivastigmine, which potentiate cholinergic signaling.18,19 These treatments not only provide improvements in cognitive symptoms associated with AD,20,21 but also show efficacy in treating the psychiatric symptoms.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 7,
      "target": 1,
      "key": "d8bc2011f9693ed7e681ff032e3939a7594c8dd286c9ef4932fff4381d71be582cb3971ebe63baef931201e5875473ce16d7a22b543ec9a51a5bee5aec1a926f"
    },
    {
      "line": 260,
      "relation": "increases",
      "evidence": "The current primary treatments for AD symptoms are acetylcholinesterase inhibitors (AChEIs) such as donepezil, tacrine, galantamine, and rivastigmine, which potentiate cholinergic signaling.18,19 These treatments not only provide improvements in cognitive symptoms associated with AD,20,21 but also show efficacy in treating the psychiatric symptoms.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 1,
      "target": 47,
      "key": "6cbed0389a072581dd7023b4bc5bcb0002e7816bee22edc7091de8d5efa3f7a71d49ba0fcf8d2352cb54d07304f7ace8f6f1ca04a510ff64117e40fcf6e08ebe"
    },
    {
      "line": 261,
      "relation": "increases",
      "evidence": "The current primary treatments for AD symptoms are acetylcholinesterase inhibitors (AChEIs) such as donepezil, tacrine, galantamine, and rivastigmine, which potentiate cholinergic signaling.18,19 These treatments not only provide improvements in cognitive symptoms associated with AD,20,21 but also show efficacy in treating the psychiatric symptoms.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 1,
      "target": 51,
      "key": "a82a5bdf5d341f3bca5eefe7a719ff8cc5b08ef5d003b31e854b64da28e0c38b8bdd36ac36e43080e93c3a3b286909d97021ae406930bf2d5ec1ba82edcd9856"
    },
    {
      "line": 262,
      "relation": "increases",
      "evidence": "The current primary treatments for AD symptoms are acetylcholinesterase inhibitors (AChEIs) such as donepezil, tacrine, galantamine, and rivastigmine, which potentiate cholinergic signaling.18,19 These treatments not only provide improvements in cognitive symptoms associated with AD,20,21 but also show efficacy in treating the psychiatric symptoms.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 1,
      "target": 83,
      "key": "f396d9a36f1f7e1f338f5626d7e40fe6ed378a438934fc93a21db452e7486dafd971a028d8ec69dff57deecc0909a610aa39c72c36d6672a136be8a4b4e27047"
    },
    {
      "line": 272,
      "relation": "association",
      "evidence": "Unfortunately, cardiovascular and gastrointestinal side effects are often observed with these treatments, effects thought to be mediated by peripherally located ACh receptors. Despite this, AChEIs remain modestly beneficial for treating AD and other forms of dementia.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 1,
      "target": 25,
      "key": "73d8095905051171f564369d221ae6d435e90df693c143a1249ba9f83bf7155c1dbefd8af8c0ab3d04bd5b79ba703f17817a895383fa53ec7983e714fb8e7d34"
    },
    {
      "line": 273,
      "relation": "association",
      "evidence": "Unfortunately, cardiovascular and gastrointestinal side effects are often observed with these treatments, effects thought to be mediated by peripherally located ACh receptors. Despite this, AChEIs remain modestly beneficial for treating AD and other forms of dementia.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 1,
      "target": 30,
      "key": "b150ca9e8f37f38f2817d60d0e99cca7754f25420d6ecf8a2c07ad70bd05db1ddbb1df8412d7502a8f23e8c0b5c681b09fa279bbb036d19523151d62937bc0b7"
    },
    {
      "line": 257,
      "relation": "isA",
      "evidence": "The current primary treatments for AD symptoms are acetylcholinesterase inhibitors (AChEIs) such as donepezil, tacrine, galantamine, and rivastigmine, which potentiate cholinergic signaling.18,19 These treatments not only provide improvements in cognitive symptoms associated with AD,20,21 but also show efficacy in treating the psychiatric symptoms.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 11,
      "target": 1,
      "key": "289984a991dd67d5c2ba8470c8d8e106accbc5feef8d72e03fa9a7cdbb3762154eef8c72fffc39e8e10ca6589182db3557c93f545d8911de8137bb08f2fa243f"
    },
    {
      "line": 258,
      "relation": "isA",
      "evidence": "The current primary treatments for AD symptoms are acetylcholinesterase inhibitors (AChEIs) such as donepezil, tacrine, galantamine, and rivastigmine, which potentiate cholinergic signaling.18,19 These treatments not only provide improvements in cognitive symptoms associated with AD,20,21 but also show efficacy in treating the psychiatric symptoms.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 8,
      "target": 1,
      "key": "b6d45eae68f0f56b8f260b4dbc1dfde9fef48f9b79b127c1ff46b263dbd877367e063cf60de7d383622d79cfbd1fb39ee7a5b8b3a0f19275287c5bbcce2c9f7f"
    },
    {
      "line": 259,
      "relation": "isA",
      "evidence": "The current primary treatments for AD symptoms are acetylcholinesterase inhibitors (AChEIs) such as donepezil, tacrine, galantamine, and rivastigmine, which potentiate cholinergic signaling.18,19 These treatments not only provide improvements in cognitive symptoms associated with AD,20,21 but also show efficacy in treating the psychiatric symptoms.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 9,
      "target": 1,
      "key": "65d9db804800c3d64d75c6f83efe790faae3b96a224fb070652f62583752cc019768d413f9b381cf01c8ea39ac52f9136ef1915d6e1b37705891d1084582ee54"
    },
    {
      "line": 321,
      "relation": "association",
      "evidence": "Furthermore, administration of nonselective muscarinic antagonists can induce cognitive deficits and psychosis in humans,16,37 indicating that mAChR activation may provide pro-cognitive and antipsychotic efficacy.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 83,
      "target": 32,
      "key": "909b7016dbb9778e2c38a8f527b57e5cf9957ad073eb80d65ed68627b855806f90a0337a7fcdc86cc77a116662a994d98f2142ecf9acf09ef0a6c269c54e67f3"
    },
    {
      "line": 272,
      "relation": "association",
      "evidence": "Unfortunately, cardiovascular and gastrointestinal side effects are often observed with these treatments, effects thought to be mediated by peripherally located ACh receptors. Despite this, AChEIs remain modestly beneficial for treating AD and other forms of dementia.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 25,
      "target": 1,
      "key": "34262d691992a73748c56302df872ff9edc292252a540bee7eb08c852ff80038e6e07fec8e71cc1d41de726ee2f0fcc202d84dba2a2fd0a83e39984559d26691"
    },
    {
      "line": 273,
      "relation": "association",
      "evidence": "Unfortunately, cardiovascular and gastrointestinal side effects are often observed with these treatments, effects thought to be mediated by peripherally located ACh receptors. Despite this, AChEIs remain modestly beneficial for treating AD and other forms of dementia.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 30,
      "target": 1,
      "key": "1baf0a4b1001954ee5028be3f144e6068a0b4313a9f56faf54ac24d359f8949addaa4d2d36197e0f7d473e350bf5428db777f77c073cf563790da3490e784520"
    },
    {
      "line": 357,
      "relation": "association",
      "evidence": " In addition, xanomeline produced statistically significant improvements in verbal learning and short-term memory, indicating efficacy in treating cognitive symptoms.40 Unfortunately, gastrointestinal side effects were observed, and dose limitations have removed it from consideration for long-term clinical use.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 30,
      "target": 12,
      "key": "7a93afdb9824536a86c71e79e863dcd6e89ba08491d7d0a101000cca709b760b4edded7e39f894affc68db317f39258a0891c14ecfe28c505925f5992c6352df"
    },
    {
      "line": 286,
      "relation": "biomarkerFor",
      "evidence": "The hallmark psychotic symptoms of SZ are the positive cluster and include auditory hallucinations, delusional beliefs, and disorganized thoughts and speech. SZ patients also exhibit negative symptoms, including anhedonia, dysfunctional social interactions, and poverty of thoughts and speech, as well as cognitive disturbances affecting several behavioral domains, including working memory, attention, and executive function",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 89,
      "target": 96,
      "key": "c66ce0c48fd6b70bf05802a212d69f91f7a489849ae98b22b1cf82deb8eee402005ca749a4f2abfd60c7d175ce431068fca1c77085811015f219d42043fa4e0d"
    },
    {
      "line": 287,
      "relation": "biomarkerFor",
      "evidence": "The hallmark psychotic symptoms of SZ are the positive cluster and include auditory hallucinations, delusional beliefs, and disorganized thoughts and speech. SZ patients also exhibit negative symptoms, including anhedonia, dysfunctional social interactions, and poverty of thoughts and speech, as well as cognitive disturbances affecting several behavioral domains, including working memory, attention, and executive function",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 88,
      "target": 96,
      "key": "d77caa48a3cf3b8f488cf543f3e08754ba376af020ce8148a60d3ec179fd6ed60834e3e03b090181e37135adbb428888396610ae469edcaed35d0de4381c8158"
    },
    {
      "line": 288,
      "relation": "association",
      "evidence": "The hallmark psychotic symptoms of SZ are the positive cluster and include auditory hallucinations, delusional beliefs, and disorganized thoughts and speech. SZ patients also exhibit negative symptoms, including anhedonia, dysfunctional social interactions, and poverty of thoughts and speech, as well as cognitive disturbances affecting several behavioral domains, including working memory, attention, and executive function",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 82,
      "target": 96,
      "key": "dc5c6d3d191895c9ca3ea4ccc19c4a9555af21b2af78c51915c82122155e031078b95682641ce79c5e7fb46ea7dfe810317ee0c136b862ebee891a048ba73476"
    },
    {
      "line": 289,
      "relation": "association",
      "evidence": "The hallmark psychotic symptoms of SZ are the positive cluster and include auditory hallucinations, delusional beliefs, and disorganized thoughts and speech. SZ patients also exhibit negative symptoms, including anhedonia, dysfunctional social interactions, and poverty of thoughts and speech, as well as cognitive disturbances affecting several behavioral domains, including working memory, attention, and executive function",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 91,
      "target": 96,
      "key": "9d5bf7eae67e35b7ef687107051d36df5827c7ec64889d6df3220eb3f314e95acd2a201910847a72914942faecb9078619b40ca90ed6b1c62a34bd7abdcbca8c"
    },
    {
      "line": 290,
      "relation": "association",
      "evidence": "The hallmark psychotic symptoms of SZ are the positive cluster and include auditory hallucinations, delusional beliefs, and disorganized thoughts and speech. SZ patients also exhibit negative symptoms, including anhedonia, dysfunctional social interactions, and poverty of thoughts and speech, as well as cognitive disturbances affecting several behavioral domains, including working memory, attention, and executive function",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 81,
      "target": 96,
      "key": "5c01f1e700da364a4614f4807ac74a4dbfa7bcabf12cc8f739984955adb660c08d09b5e5b05743883af968cc40d3e9e01d607793e8b8fb13c58377a139cb171b"
    },
    {
      "line": 302,
      "relation": "regulates",
      "evidence": "Current treatments include both typical (eg, haloperidol and chlorpromazine) and atypical (eg, risperidone and clozapine) antipsychotics, which act on the dopaminergic system and D2 dopamine receptors in particular. These treatments show partial efficacy in reducing psychotic or positive symptoms;30 however, they demonstrate little to no efficacy in addressing negative symptoms and cognitive impairments, which can prevent patients from participating fully and productively in society",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 3,
      "target": 70,
      "key": "c120fad6c975f8056ff150b0382e8f57b006eed7e4ca66e65dbc53904a2ac68dd9bee3b9a317915338ba273c7f4d4b57341fab7734f410acf61aa83467c33c3d"
    },
    {
      "line": 303,
      "relation": "causesNoChange",
      "evidence": "Current treatments include both typical (eg, haloperidol and chlorpromazine) and atypical (eg, risperidone and clozapine) antipsychotics, which act on the dopaminergic system and D2 dopamine receptors in particular. These treatments show partial efficacy in reducing psychotic or positive symptoms;30 however, they demonstrate little to no efficacy in addressing negative symptoms and cognitive impairments, which can prevent patients from participating fully and productively in society",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 3,
      "target": 51,
      "key": "35eb83af105fdbcd72a6f9b5c7f26444026eb3bdefa2148bfdf56ee1fa19751d9456ddd6dd2c953f496c8ffa02fb6355fffd2d0dfc162e5b10782586d0afbfd0"
    },
    {
      "line": 312,
      "relation": "association",
      "evidence": "Accumulating evidence suggests that the three clusters of SZ symptoms cannot be ascribed solely to alterations in monoaminergic signaling as dysregulation of glutamatergic, gamma-aminobutyric acid (GABA)-ergic, and cholinergic systems have also been reported",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 49,
      "target": 96,
      "key": "bb2d80ea3982e6b502bb77c413a2626e71ab71731cf62695a50da75152741d9f9d3801c8f421cd72e10f67367d4ca5aa5347a31d55c398627bb1a12dd9cb3b59"
    },
    {
      "line": 313,
      "relation": "association",
      "evidence": "Accumulating evidence suggests that the three clusters of SZ symptoms cannot be ascribed solely to alterations in monoaminergic signaling as dysregulation of glutamatergic, gamma-aminobutyric acid (GABA)-ergic, and cholinergic systems have also been reported",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 44,
      "target": 96,
      "key": "9c0e2da5d6826abfac09c1b476a1f92848665890fa5d793fdb2fbfbe4dd81180f58a1cea304330e638ce8d8cf677c7187b57c72d13273024c232d80db1cc3935"
    },
    {
      "line": 336,
      "relation": "increases",
      "evidence": "Of these, the M1/M4 -preferring agonist xanomeline was the only one to progress to a phase III clinical trial, where it was assessed for efficacy in ameliorating cognitive deficits observed in AD patients. While xanomeline showed a trend toward improving cognitive function in these patients, this effect did not reach statistical significance. However, this agonist did produce surprisingly robust and dose-dependent reductions in hallucinations, delusions, vocal outbursts, and other behavioral disturbances in these patients",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 12,
      "target": 51,
      "key": "a960a4ca2ff4d54a57241546e38f14badd645bc946f09d5d20544e1b3e34bf60731ad8f0272ce79dc23f8cd90e641f6f0c4b388796bbf85b9228226af2626f90"
    },
    {
      "line": 337,
      "relation": "decreases",
      "evidence": "Of these, the M1/M4 -preferring agonist xanomeline was the only one to progress to a phase III clinical trial, where it was assessed for efficacy in ameliorating cognitive deficits observed in AD patients. While xanomeline showed a trend toward improving cognitive function in these patients, this effect did not reach statistical significance. However, this agonist did produce surprisingly robust and dose-dependent reductions in hallucinations, delusions, vocal outbursts, and other behavioral disturbances in these patients",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 12,
      "target": 95,
      "key": "2be3b086f71e76bc13e901861738b409d8da1752994bb0a64e7b4e37145ef3bb8cb58ee25026884b08e92923b0d7ca8ce3c68191d23a886152e745a3a548d8e3"
    },
    {
      "line": 338,
      "relation": "decreases",
      "evidence": "Of these, the M1/M4 -preferring agonist xanomeline was the only one to progress to a phase III clinical trial, where it was assessed for efficacy in ameliorating cognitive deficits observed in AD patients. While xanomeline showed a trend toward improving cognitive function in these patients, this effect did not reach statistical significance. However, this agonist did produce surprisingly robust and dose-dependent reductions in hallucinations, delusions, vocal outbursts, and other behavioral disturbances in these patients",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 12,
      "target": 92,
      "key": "549246301515efa5b886e2caa66a40c5000ee85e1a96457fa664c8a4e742e006a750334be22cebf6a20d2d4ddf30fd3aeff57cea84ac9bf75939ededef782820"
    },
    {
      "line": 346,
      "relation": "decreases",
      "evidence": "This study reported that xanomeline treatment produced robust improvements in both the positive and the negative symptoms of patients with SZ",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 12,
      "target": 96,
      "key": "16f3c02f8fb0122e1d8d4b88cfbea90e24340b33de56df592de12d0edf23f0203040e965102a5220ee8c05d8c0b63d8d9fe2a0bd4c960ea11594576f75b221d1"
    },
    {
      "line": 355,
      "relation": "increases",
      "evidence": " In addition, xanomeline produced statistically significant improvements in verbal learning and short-term memory, indicating efficacy in treating cognitive symptoms.40 Unfortunately, gastrointestinal side effects were observed, and dose limitations have removed it from consideration for long-term clinical use.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 12,
      "target": 52,
      "key": "a61ca26cf8e2e076cf0b2cecf1c89960b72fa28ef83e06d69c58fd88aa020d00625f85b3c71352bc2178e88d4c6064baa86b09164cf0b999e75a201c697249bb"
    },
    {
      "line": 356,
      "relation": "increases",
      "evidence": " In addition, xanomeline produced statistically significant improvements in verbal learning and short-term memory, indicating efficacy in treating cognitive symptoms.40 Unfortunately, gastrointestinal side effects were observed, and dose limitations have removed it from consideration for long-term clinical use.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 12,
      "target": 82,
      "key": "4e9dae985ff09356116e78e911dffa2371beeab149c7ec4217b5d180bd1034b86721605e11f5712a37522b8c87e36de7dab897ac91a2f77057740f6d3fab30eb"
    },
    {
      "line": 357,
      "relation": "association",
      "evidence": " In addition, xanomeline produced statistically significant improvements in verbal learning and short-term memory, indicating efficacy in treating cognitive symptoms.40 Unfortunately, gastrointestinal side effects were observed, and dose limitations have removed it from consideration for long-term clinical use.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 12,
      "target": 30,
      "key": "fe5580f57e40a0c9db78dece1946d93d999c5d52ab95f1b47700603ecba8a1776132c2fd3c2d652f9fc3851d0997429983a45a2dd54c60cf1ac44e8a366b52f2"
    },
    {
      "line": 574,
      "relation": "increases",
      "evidence": "Both VU0152100 and VU0152099 effectively reversed amphetamine-induced hyperlocomotion, demonstrating antipsychotic-like activity in preclinical models.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 5,
      "target": 53,
      "key": "bade41e20fab94030ad73e68e3fe574c8d0e842651ba8d2e11af05bfa7ded0f189af5c9a89719c9d11f3ea0a410f3b2775e9ec48e1343812b1a0960478cc01d0"
    },
    {
      "line": 382,
      "relation": "regulates",
      "evidence": "N-methyl-D-aspartate (NMDA) receptors play a critical role in regulating synaptic plasticity, and disrupted NMDA-receptor neurotransmission is thought to underlie the cognitive deficits observed in numerous psychiatric diseases.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 75,
      "target": 56,
      "key": "39c068bb7b451335b58728b777e637676bac761f08cc653ff7dfee8253b1b812128305d8906aad5b0c6ad987bc7a2e6e83693d30567be59febbd3a5f2d24090f"
    },
    {
      "line": 383,
      "relation": "association",
      "evidence": "N-methyl-D-aspartate (NMDA) receptors play a critical role in regulating synaptic plasticity, and disrupted NMDA-receptor neurotransmission is thought to underlie the cognitive deficits observed in numerous psychiatric diseases.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 75,
      "target": 51,
      "key": "3ce7d16cc47c70923baa0cf85e31babf2006d1c843f3039e63b28a6a0935e500ab6d09038d8816304957f8d4120e3c26bdc1add538ebd544412078504082975c"
    },
    {
      "line": 401,
      "relation": "association",
      "evidence": "M1 mAChRs have been demonstrated to potentiate NMDA-receptor signaling in the hippocampus and cortex,48,49 brain areas intimately associated with learning and memory. In addition, M1 KO mice displayed reduced hippocampal long-term potentiation, a mechanism heavily implicated in learning and memory. Behaviorally, M1 KO animals display deficits in several medial prefrontal cortex-dependent cognitive tasks, including non-matching-to- sample, win-shift radial arm maze, and social discrimination tasks.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 45,
      "target": 52,
      "key": "ade28a5f8d2c9f339caeb8cea67093c4575fc369d8f4d313e6fb5f226f21471cdce289f4e07fdb39f46cdf5e9ac03ff3c551dcc5d39f319ce4d86b1021d53ac0"
    },
    {
      "line": 402,
      "relation": "association",
      "evidence": "M1 mAChRs have been demonstrated to potentiate NMDA-receptor signaling in the hippocampus and cortex,48,49 brain areas intimately associated with learning and memory. In addition, M1 KO mice displayed reduced hippocampal long-term potentiation, a mechanism heavily implicated in learning and memory. Behaviorally, M1 KO animals display deficits in several medial prefrontal cortex-dependent cognitive tasks, including non-matching-to- sample, win-shift radial arm maze, and social discrimination tasks.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        }
      },
      "source": 45,
      "target": 54,
      "key": "fb0467f38c7a7cee810f15d823547049a64779ad86bf016858e3675d3ff7956be97ea567cbbb37b8dc11c5613d24799592c22571cd66650996da3a1af145d029"
    },
    {
      "line": 413,
      "relation": "decreases",
      "evidence": "Finally, studies in mice exhibiting AD-like Abeta plaque pathologies found that deletion of M1 increased amyloidogenic processes, suggesting that M1 may play a role in regulating AD disease progression.51",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 77,
      "target": 2,
      "key": "a3facb8f9eacbcd2880e306e27ddf96c10b4fb2c8f4fe347f0613a66578626f902cdc8d548b0d45fec7e5f6ff135534f1e371cb9cdf0a6e80cfb526cfbc687c9"
    },
    {
      "line": 424,
      "relation": "increases",
      "evidence": "Subsequent optimization produced two analogs of AC-42 (AC-260584 and 77-LH-28-1), which maintained M1 selectivity and possessed properties suitable for use in animal models. Both AC-260584 and 77-LH-28-1 displayed antipsychotic and cognition-enhancing efficacy in pre-clinical models",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 23,
      "target": 65,
      "key": "3eaf8417f3b1eb2499431f0b179a626a68f5b72b3ddb3cdbcb8745514f898e4550496a56fdf0d0c297441c0f6bc7320774e75ff84eadfc2935e2de3b271cbab6"
    },
    {
      "line": 426,
      "relation": "increases",
      "evidence": "Subsequent optimization produced two analogs of AC-42 (AC-260584 and 77-LH-28-1), which maintained M1 selectivity and possessed properties suitable for use in animal models. Both AC-260584 and 77-LH-28-1 displayed antipsychotic and cognition-enhancing efficacy in pre-clinical models",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 19,
      "target": 65,
      "key": "7f84053c9910be4dc31de9c753d6711e3ba44cf566c6c288b47dc02a308c4d3772e2d1728f0dfcce0455658ba32798681219273726abe23a225151dcb949af89"
    },
    {
      "line": 436,
      "relation": "increases",
      "evidence": "Another early allosteric agonist, TBPB (1-(1’-(2-methylbenzyl) -1,4’-bipiperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-1), also exhibited impressive selectivity for M1 mAChRs and potentiated NMDA receptor currents in CA1 hippocampal cells. ",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "CA1 Region, Hippocampal": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 18,
      "target": 65,
      "key": "0539f2179812eb31fa241b06a2eb95033321b9168fae279c4058799f78dd4cec13a7d2dcbe142eb80381bb36ce715b3f6c9c423571435df613356a0bbaf0d828"
    },
    {
      "line": 448,
      "relation": "decreases",
      "evidence": "Moreover, additional pre-clinical studies with TBPB demonstrated efficacy in reducing antipsychotic-like behaviors and in reversing scopolamine-impaired acquisition of contextual fear.59 Studies in cell lines also demonstrated that TBPB promoted a non-amyloidogenic pathway and decreased Abeta production, indicating that M1 modulation may have efficacy in the treatment of both symptomatic and pathologic features of AD",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 18,
      "target": 10,
      "key": "b9821523aedbf342a1bea6d68aeae8588d15b78af6d2007e2344eb210c217dc1ee20a40d887487427b99db495d8e7d1da937378eb39ff41383811a1b849e1cc6"
    },
    {
      "line": 450,
      "relation": "decreases",
      "evidence": "Moreover, additional pre-clinical studies with TBPB demonstrated efficacy in reducing antipsychotic-like behaviors and in reversing scopolamine-impaired acquisition of contextual fear.59 Studies in cell lines also demonstrated that TBPB promoted a non-amyloidogenic pathway and decreased Abeta production, indicating that M1 modulation may have efficacy in the treatment of both symptomatic and pathologic features of AD",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 18,
      "target": 2,
      "key": "5faa6a2913d24181c978c342e484ab07384275ed85764b833b4457e1c19b2936119afe832af6b4e00f22a5f4414c2668acb8a39d723497e87f4ee0807abd901a"
    },
    {
      "line": 449,
      "relation": "decreases",
      "evidence": "Moreover, additional pre-clinical studies with TBPB demonstrated efficacy in reducing antipsychotic-like behaviors and in reversing scopolamine-impaired acquisition of contextual fear.59 Studies in cell lines also demonstrated that TBPB promoted a non-amyloidogenic pathway and decreased Abeta production, indicating that M1 modulation may have efficacy in the treatment of both symptomatic and pathologic features of AD",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 10,
      "target": 39,
      "key": "98b0b4f6f1ad16c6e732ea43dc84194ec2a1d12c709f98c9f9d39c7d8bebd9854a3414167a5b0d25c1f1dd193ed1c6261c7d179e7f0a01c88a3fe8c7bd03686d"
    },
    {
      "line": 458,
      "relation": "increases",
      "evidence": "More recently, the M1-selective allosteric agonist VU0357017 was discovered, which displayed improved potency via binding to a novel allosteric site on the M1 mAChR. VU0357017 significantly blocked scopolamine-impaired contextual fear conditioning and enhanced spatial and contextual fear learning",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 38,
      "target": 59,
      "key": "38dfdf8380bee07de3629b5adbb65af5baf241b4d01d68ca6ccb54f913703f5f3a2261d6d60bb8dcab2d81a4c92bfe2bbb555baaf74e6d7676b827d7c5b8d272"
    },
    {
      "line": 460,
      "relation": "decreases",
      "evidence": "More recently, the M1-selective allosteric agonist VU0357017 was discovered, which displayed improved potency via binding to a novel allosteric site on the M1 mAChR. VU0357017 significantly blocked scopolamine-impaired contextual fear conditioning and enhanced spatial and contextual fear learning",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 38,
      "target": 10,
      "key": "47ed8c96bc12118be99f3b4acd122fa5b3a913940c83a6c5046172f9b92aad851381f94a82fc4e423cc35849fdfc46845c8a45353bd0bb6277982177da503fc6"
    },
    {
      "line": 461,
      "relation": "increases",
      "evidence": "More recently, the M1-selective allosteric agonist VU0357017 was discovered, which displayed improved potency via binding to a novel allosteric site on the M1 mAChR. VU0357017 significantly blocked scopolamine-impaired contextual fear conditioning and enhanced spatial and contextual fear learning",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 38,
      "target": 39,
      "key": "51f3dcfeb79aecc9129ec218455bbdcd87b120168c3531408903a17c805c67194fc901fbef94f7d3c0ed74eda32127b22bd95af9d9cd800837af525241420420"
    },
    {
      "relation": "hasComponent",
      "source": 59,
      "target": 38,
      "key": "fac7c321b21ea6dcf72a931415ee4e8feb6f591570c23e13919328dc1333df6b2318db3fadd707c434713c8adb6891da650899b7e74db52781985ba6b13861fa"
    },
    {
      "relation": "hasComponent",
      "source": 59,
      "target": 65,
      "key": "c480bc89df79572dbf53a935a28db46ccb3433632325242ee13c57c12411337f5b148b5734ce360bc23eaef2d866c65dcedeeb5c16f3e51ad54b10bd706763f7"
    },
    {
      "line": 459,
      "relation": "increases",
      "evidence": "More recently, the M1-selective allosteric agonist VU0357017 was discovered, which displayed improved potency via binding to a novel allosteric site on the M1 mAChR. VU0357017 significantly blocked scopolamine-impaired contextual fear conditioning and enhanced spatial and contextual fear learning",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 59,
      "target": 65,
      "key": "607a4302c53159b4c422af4d40d7eb9ab73892708ebed7b65d6d9446be2f88719f60ae4c75166efcccef6ab0d35c13fb536d52aabe05f7ceb7a8249c10901379"
    },
    {
      "relation": "hasComponent",
      "source": 58,
      "target": 29,
      "key": "d6a9db042341422af07625e5ecfb71c685a851543b034fa43af2a1dab264790d514d0bcaa3784796ce7a3f1e7497aba8c7d6bb337d205db8740188c268a749f8"
    },
    {
      "relation": "hasComponent",
      "source": 58,
      "target": 65,
      "key": "3f5f1dd0a982ab43e301990243fa861155ad6f2d034bfc30c35d08a2bae5eb427c8996321c9b2be4e029987651d9486c74aed0926636c7a7f9536012d08d1d5d"
    },
    {
      "line": 469,
      "relation": "increases",
      "evidence": "A recent clinical study utilizing the M1-selective allosteric agonist GSK1034702 demonstrated pro-cognitive efficacy in a nicotine abstinence model of episodic memory impairment in smokers, 67 providing exciting evidence that M1-selective activation can provide pro-cognitive benefits in humans",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 58,
      "target": 51,
      "key": "4ce4a6270167637807aa3cd5009bfb2960d69a3c37277c10f51aec1b9de17d454c243782416facfc537301d0d1f1a3710a8d509b21b78db44bd6aab2e74b61af"
    },
    {
      "line": 478,
      "relation": "increases",
      "evidence": "The first subtype-selective M1 PAM to be characterized was benzyl quinolone carboxylic acid (BQCA);68 BQCA exhibited high selectivity with no activity at mAChR subtypes M2–M5 and induced up to a 129-fold leftward shift in ACh potency at the M1 mAChR",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 20,
      "target": 65,
      "key": "0b073af9068912ea52a9e142e75add0443b6284664ce7a527c1f279b0e7d029effc2f42ad948dc52e7ad2ea022851fb1db56f44b9f07348c1d217ba6b1c474b9"
    },
    {
      "line": 491,
      "relation": "increases",
      "evidence": "In brain slice electrophysiology studies, BQCA enhanced excitatory postsynaptic currents in medial prefrontal cortical neurons,69 an area critical for higher cognitive, learning, and memory functions.70 In pre-clinical animal studies, BQCA reversed scopolamine-impaired contextual fear conditioning and rescued medial prefrontal cortex-dependent discrimination reversal learning deficits in a transgenic mouse model of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Prefrontal Cortex": true
        }
      },
      "source": 20,
      "target": 43,
      "key": "4d5ac17d94599134470a41b5e687138606b084b57f12ff15f53b977239e644926231cb1c1ef38733ca27e0e2104b7b7d0e9edd6f369f1fef4eb980be84f75741"
    },
    {
      "line": 500,
      "relation": "decreases",
      "evidence": "In brain slice electrophysiology studies, BQCA enhanced excitatory postsynaptic currents in medial prefrontal cortical neurons,69 an area critical for higher cognitive, learning, and memory functions.70 In pre-clinical animal studies, BQCA reversed scopolamine-impaired contextual fear conditioning and rescued medial prefrontal cortex-dependent discrimination reversal learning deficits in a transgenic mouse model of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 20,
      "target": 10,
      "key": "379bc6e8ca7ca8f3bcafb0cf723e5980224bc79f8d2869b88d86dbe5779d29bcd92c38bdd4ae2dab303bc633e108981fa2faeb8183a010f4e4159276f57fc9bc"
    },
    {
      "line": 501,
      "relation": "increases",
      "evidence": "In brain slice electrophysiology studies, BQCA enhanced excitatory postsynaptic currents in medial prefrontal cortical neurons,69 an area critical for higher cognitive, learning, and memory functions.70 In pre-clinical animal studies, BQCA reversed scopolamine-impaired contextual fear conditioning and rescued medial prefrontal cortex-dependent discrimination reversal learning deficits in a transgenic mouse model of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 20,
      "target": 39,
      "key": "724f63d84db98286fa146feb3db1478c2243728c633531c831fdc82c59588f7330bf549c25cd8c761d56d96d1550a2d21061c04bbc764c7650a675ba2bfdbbb4"
    },
    {
      "line": 502,
      "relation": "increases",
      "evidence": "In brain slice electrophysiology studies, BQCA enhanced excitatory postsynaptic currents in medial prefrontal cortical neurons,69 an area critical for higher cognitive, learning, and memory functions.70 In pre-clinical animal studies, BQCA reversed scopolamine-impaired contextual fear conditioning and rescued medial prefrontal cortex-dependent discrimination reversal learning deficits in a transgenic mouse model of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "source": 20,
      "target": 52,
      "key": "b1054807f20b85398d2faa68f19b2b088736ebb3107474d6c0f26452a752aa6ec702bd1692e4cd4a432bfdf1beda8f0d835f0a63a5fe47bcd044342425513142"
    },
    {
      "line": 512,
      "relation": "increases",
      "evidence": "Additionally, recent studies demonstrated that BQCA was effective in reversing memory deficits in Y-maze object recognition and spontaneous alternation tasks in rats.71,72",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "Species": {
          "10116": true
        }
      },
      "source": 20,
      "target": 54,
      "key": "d8cc177485406a82a7a731b39b7d038326a5f6e9c5041581b48520a4a1da83c10cce27601aff139edf455f9fe6c39b42699d66d8539c3122b0a788d5e2bad3ea"
    },
    {
      "line": 492,
      "relation": "association",
      "evidence": "In brain slice electrophysiology studies, BQCA enhanced excitatory postsynaptic currents in medial prefrontal cortical neurons,69 an area critical for higher cognitive, learning, and memory functions.70 In pre-clinical animal studies, BQCA reversed scopolamine-impaired contextual fear conditioning and rescued medial prefrontal cortex-dependent discrimination reversal learning deficits in a transgenic mouse model of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Prefrontal Cortex": true
        }
      },
      "source": 33,
      "target": 51,
      "key": "ed5f85daee1f521e9caba03f3df8ce6678587e5d1e647a4303aeff9ebb59f2695347b79c7d37be998df9daa7bd4dd0c1a2a9e8c7bb512be70f089f3076f1e81d"
    },
    {
      "line": 493,
      "relation": "association",
      "evidence": "In brain slice electrophysiology studies, BQCA enhanced excitatory postsynaptic currents in medial prefrontal cortical neurons,69 an area critical for higher cognitive, learning, and memory functions.70 In pre-clinical animal studies, BQCA reversed scopolamine-impaired contextual fear conditioning and rescued medial prefrontal cortex-dependent discrimination reversal learning deficits in a transgenic mouse model of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Prefrontal Cortex": true
        }
      },
      "source": 33,
      "target": 52,
      "key": "fe9c043cdcc25cf76beac3408340408530985ab0e223b51c1cafb65e0f8e4123cbac3ce88884089cd8640df7564f4ac74092a54cb026aa7d9456bcd98447c35c"
    },
    {
      "line": 494,
      "relation": "association",
      "evidence": "In brain slice electrophysiology studies, BQCA enhanced excitatory postsynaptic currents in medial prefrontal cortical neurons,69 an area critical for higher cognitive, learning, and memory functions.70 In pre-clinical animal studies, BQCA reversed scopolamine-impaired contextual fear conditioning and rescued medial prefrontal cortex-dependent discrimination reversal learning deficits in a transgenic mouse model of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Prefrontal Cortex": true
        }
      },
      "source": 33,
      "target": 54,
      "key": "5a2976d64bf1f3096f4ebc3b63bfdf163970f5e4a18e7a9aa2ed14f31b97b13b4a26a085d9b1dcfdd2cff5ac4216582262151fdea35dfc79fc8ea24b4541217c"
    },
    {
      "line": 521,
      "relation": "increases",
      "evidence": "Recent drug discovery efforts in our group have yielded novel M1-selective PAMs VU0405652 (ML169) and VU0456940, both of which potentiate M1-mediated non-amyloidogenic amyloid precursor protein (APPsalpha) processing, suggesting disease-modifying potential in AD",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 34,
      "target": 65,
      "key": "804a3e3cecd0ffea82e78fe77e7fb0685b3a126fbb44cf90086f8acacc785d9ab273ee0dea5534a0fbddd8eb2ba63fc5e93b359837f7c5432c05166c4087c919"
    },
    {
      "line": 522,
      "relation": "increases",
      "evidence": "Recent drug discovery efforts in our group have yielded novel M1-selective PAMs VU0405652 (ML169) and VU0456940, both of which potentiate M1-mediated non-amyloidogenic amyloid precursor protein (APPsalpha) processing, suggesting disease-modifying potential in AD",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 16,
      "target": 65,
      "key": "889b8d609ddd6e5f125b9e654b4c4f77f769b15448759c1d28824cab6cc93fcd0debf9263c61aebd1f57e81409c3155b7f5a4ad045c5378fc53ddf70cec4e6a2"
    },
    {
      "line": 532,
      "relation": "decreases",
      "evidence": "Conversely, the nonselective mAChR agonist BuTAC ([5R-(exo)]-6-[4-butylthio-1,2,5-thiadiazol-3-yl]-1-azabicyclo-[3.2.1]-octane) shows an antipsychotic profile when tested in numerous preclinical animal models. Administration of BuTAC reduces apomorphine-induced climbing and apomorphine-induced disruptions of prepulse inhibition78,79 and reduces conditioned avoidance responding in wild-type, but not M4 KO mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 24,
      "target": 6,
      "key": "0215af2cabf4f5c3b5a3bb904feac087f41144646d9bd851919ec30e2ec4e72bd75fb36bc0b54f4d1e00552b1675d057d39a5f3efaf01ff9aec5cab2cb64b90d"
    },
    {
      "line": 534,
      "relation": "decreases",
      "evidence": "Conversely, the nonselective mAChR agonist BuTAC ([5R-(exo)]-6-[4-butylthio-1,2,5-thiadiazol-3-yl]-1-azabicyclo-[3.2.1]-octane) shows an antipsychotic profile when tested in numerous preclinical animal models. Administration of BuTAC reduces apomorphine-induced climbing and apomorphine-induced disruptions of prepulse inhibition78,79 and reduces conditioned avoidance responding in wild-type, but not M4 KO mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 24,
      "target": 79,
      "key": "f3396f6d400379ce9c9413cfa24489d549b40b2467bfe1eb82b6a81f06189e315b82dbb69f50f7ce466bf313e990a8f583e800560996faaaa6f3ba91ec599713"
    },
    {
      "line": 533,
      "relation": "decreases",
      "evidence": "Conversely, the nonselective mAChR agonist BuTAC ([5R-(exo)]-6-[4-butylthio-1,2,5-thiadiazol-3-yl]-1-azabicyclo-[3.2.1]-octane) shows an antipsychotic profile when tested in numerous preclinical animal models. Administration of BuTAC reduces apomorphine-induced climbing and apomorphine-induced disruptions of prepulse inhibition78,79 and reduces conditioned avoidance responding in wild-type, but not M4 KO mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 6,
      "target": 46,
      "key": "df3b665d1895c7082979321db658a51d0309d4d4b0a48de4896c496ad638ef172f3493cfbd0e3071c6c2b1c1cb3633337ac6360d9e953ae8395050652d2f8873"
    },
    {
      "line": 581,
      "relation": "decreases",
      "evidence": "LY2033298, a structurally distinct M4-selective PAM, was similarly efficacious in several preclinical models of psychosis, including conditioned avoidance responding and apomorphine-impaired prepulse inhibition",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 6,
      "target": 46,
      "key": "cb9cb7ddba4da1f66fa9909c877cf3dcfd4bb935142328f6dfa746a2ec265521be7e2f3f5167726172ab28b51f5c2653158700d0bfa1cef47923bc0d924c61a9"
    },
    {
      "line": 535,
      "relation": "association",
      "evidence": "Conversely, the nonselective mAChR agonist BuTAC ([5R-(exo)]-6-[4-butylthio-1,2,5-thiadiazol-3-yl]-1-azabicyclo-[3.2.1]-octane) shows an antipsychotic profile when tested in numerous preclinical animal models. Administration of BuTAC reduces apomorphine-induced climbing and apomorphine-induced disruptions of prepulse inhibition78,79 and reduces conditioned avoidance responding in wild-type, but not M4 KO mice.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 79,
      "target": 68,
      "key": "8ac6be87b2200cd6b54e772c4c7daa4bc948a88019024cd91073c1fb7fd5d75e3175fe9748047b86119da8dacd2b68a5a279eaab5ec3274727777a22c8a60b10"
    },
    {
      "line": 544,
      "relation": "association",
      "evidence": "The M4 receptor is highly expressed in the striatum, hippocampus, and neocortex,45,46 suggesting that this mAChR subtype is ideally located to modulate dopaminergic signaling. In support of this hypothesis, M4 KO mice exhibit a hyperdopaminergic phenotype that is resistant to mAChR agonist-induced attenuation of dopamine levels.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 28,
      "target": 68,
      "key": "55d392b30ffe683bdfc620016fde02a6e1ce75a137af8abebdb22563df17f7e53438f1982549ac185576cca665be09d6d6903323a8cfb62221f4c65e7f743eb0"
    },
    {
      "line": 545,
      "relation": "association",
      "evidence": "The M4 receptor is highly expressed in the striatum, hippocampus, and neocortex,45,46 suggesting that this mAChR subtype is ideally located to modulate dopaminergic signaling. In support of this hypothesis, M4 KO mice exhibit a hyperdopaminergic phenotype that is resistant to mAChR agonist-induced attenuation of dopamine levels.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "source": 36,
      "target": 68,
      "key": "4ff8b2f4b417425b64863bc64ff3db1965b20eea05cf48060a13f9667d10c1ff1f8b4d31f4d36af077bb5f622808611867c8b6b2f203aeab1e5d3bd0c683ed98"
    },
    {
      "line": 553,
      "relation": "increases",
      "evidence": "Two novel M4-selective compounds, VU10010 and LY2033298, represented a breakthrough when they were described in 2008.84,85 VU10010 is a potent M4-selective PAM that increases affinity/efficacy of ACh to promote M4 mAChR activation.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 17,
      "target": 4,
      "key": "0c6bd7b0e196c6f88f87d353d4764de891832e87bf9fd0abf10682efa205595bc77f8568a1857cc55c8ae183142e664a9c589032ff4d1e30160741bb541dc2ae"
    },
    {
      "line": 563,
      "relation": "increases",
      "evidence": "In brain slices, VU10010 selectively potentiated mAChR-mediated reductions in glutamatergic, but not GABAergic, signaling in hippocampal neurons, indicating a key role for M4 in regulating hippocampal function, and possibly in modulating cognition.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 17,
      "target": 68,
      "key": "3c4d53b439d3f37ae2c21be490c12172d35ef4da0775e86ef5053cc96e09c2fee0f2a31e6b2db219e85261217d3b85d53ca1ee05f445d528a45a9b33bbbddf55"
    },
    {
      "line": 573,
      "relation": "decreases",
      "evidence": "Both VU0152100 and VU0152099 effectively reversed amphetamine-induced hyperlocomotion, demonstrating antipsychotic-like activity in preclinical models.",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 15,
      "target": 5,
      "key": "40523ee969ec650085e664500ab8c9b290b103ba3fdb9be3c1b07a8512187e35565effa1d72f98d7468f3bc68c888ac7268e3af282f95fd560bbc57b50072478"
    },
    {
      "line": 580,
      "relation": "decreases",
      "evidence": "LY2033298, a structurally distinct M4-selective PAM, was similarly efficacious in several preclinical models of psychosis, including conditioned avoidance responding and apomorphine-impaired prepulse inhibition",
      "citation": {
        "type": "PubMed",
        "reference": "24511233"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 21,
      "target": 5,
      "key": "1d86ac17aa2b27027ba94b2e335f5d0b84c8873f463c9a0090bc3d4c375db2ea142ed7f670d10e5a6cfb4f1a05fe2a088de9e293e202cb99933316cc8578d5fa"
    }
  ]
}